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ABSTRACT OF THE THESIS
TARGETING OF RIBONUCLEOTIDE REDUCTASE WITH 2'-DISULFIDE
ANALOGS OF ADENOSINE. ELECTRONIC VERSUS STERIC EFFECTS IN
RADICAL DEOXYGENATION OF FLUORINE-CONTAINING NUCLEOSIDES
by
Dania Companioni
Florida International University, 2002
Miami, Florida
Professor Stanislaw Wnuk, Ma jor Professor
Inhibition of the enzyme ribonucleotide reductase is an appealing concept for the rational
drugLi design against rapid proliferation of systems such as viruses and cancer cells.
Synthesis of 2 '-thionucleoside analogs as possible inhibitors of the enzyme was targeted
in this research. For protecting the reactive thiol group, mixed disulfides were prepared as
precursors of the sulfur-containing nucleosides. The thionucleoside obtained are currently
under biological studies.
Fluorinated compounds are widely used in biochemistry, medicinal chemistry, and
pharmacology. Synthesis of '-deoxy-'-fluoroadenosine and its arabino epimer as well as
3-deoxy-3'-fluoroadenosine and its xylo epimer were also targeted in order to study the
electronic versus steric P-fluorine effects in radical deoxygenation of fluorine containing
pentofuranose nucleosides. Our results clearly show that steric effect o f the heterocyclic
base from the 3-face of the sugar is decisive, favoring the incorporation of deuterium
from the less hindered c-face.
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1. INTRODUCTION:
1.1. GENERAL INTRODUCTION:
Studies on nucleic acids date from 1868 when Friedrich Miescher obtained a
precipitate of a phosphorus-containing substance from human pus cells which he named
nuclein. He also found this material to be common constituent of yeast, kidney, liver,
testicular, and nucleated red blood cells. In fact, his nuclein was really a nucleoprotein
and it was not until 1889 that Richard Altmann obtained the first protein-free material, to
which he gave the name nucleic acid.'
Nucleic acids are very long, thread-like polymers, made up of a linear array of
monomers called nucleotides, which are the phosphate esters of nucleosides. Ribonucleic
acid (RNA) and deoxyribon cleic acid (DNA) are the two basic kinds of nucleic acids.
RNA is made up of ribonucleotides and serves in the transcription and translation of
genetic information in cells while DNA is the repository of this information and its
monomers are 2'-deoxyribonucleotides:
All nucleotides are constructed from three components: a nitrogen heterocyclic
base, a pentose sugar, and a phosphate residue. The major bases are monocyclic
pyrimidines or bicyclic purines. The major purines are adenine (A) and guanine (G) that
are found in both DNA and RNA. The mayor pyrimidines are cytosine (C), thymine (T),
and uraci l (U) (Fig. 1). -
In nucleosides, the purine nitrogen-9 or pyrimidine nitrogen-I are attached to the
carbon-I of a pentofuranose sugar. In ribonucleic acid, the pentose is D-ribose, which is
locked into a five-membered furanose ring by a f -glycosylic linkage (Fig. 2). In DNA,
the pentose is 2-deoxy-D-ribose and the methylated pyrimidine base thyrnine takes the
place of uracil in RNA (Fig. 3).
NH 2  0 NH 2  0 0
N( N N NH N Me NH NH
N N N N H2  N'O NO N O
H H H H H
adenine guanine cytosine thymine uracii
Figure 1 Structures of the five major purine and pyrimidine bases of nucleic acids
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Figre 2 Structure of the four ribonucleosides
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deoxyadenosine deoxyguanosine deoxycytidine deoxythimidine
Figu 3 Structure of the four major deoxyribonucleosides
Ncleotides or nucleoside monophosphates are formed when phosphoric acid
esterifies a sugar -OH grou p of nucleosides. Nucleosides in which the phosphoric acid
esterifies two of the available ribose hydroxyl groups are known as cyclic nucleotides.
Nucleoside monoesters of pyrophosphoric acid an lled nucleoside diphosphates while
nucleoside esters of tripolyphosphoric acid are nucleoside triphosphates (Fig. 4).'
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Figure 4 Structure of sorne ribonucleotides
The first nucleoside syntheses were planned to prove the structures of adenosine
and the other ribo- and deoxyribonucleosides. Modern syntheses have been aimed at
producing nucleoside analogs, frequently for using them as inhibitors of nucleic acid
metabolism: Modifications of the sugar moiety of nucleotides at the 2'-position have
resulted in a number of mechanism-base inhibitors of ribonucleotide reductase. Since
nucleoside analogs have been found to show a wide and useful range of biological
activity, hundreds, if not thousands, analogs have been synthesized in pharmaceutical
laboratories across the world. In particular, chemistry of fluorine- and sulfur-modified
nucleosides62 have gained increased attention since their functionalities present in sugar
moieties have led to active compounds. In recent times, industrial targets for this work
have been anti-viral, anti-cancer, and chemotherapeutic agents.
1.2 RIII O CLEoTID I E REDUCTASES:
The deoxyribonucleotides have only one metabolic purpose: to serve as
preCurrsors foir DN synthesis. ' In most organisms, ribonucleotide diphosphates (NDPs)
are the substrates for deoxyribonucleotide formation. Reduction at the 2'-position of the
ribose ring in ND Ps produces 2'-deoxy forms of these nucleotides. This reaction involves
replacement of the 2'-OH by a hydride ion (H:-) and is catalyzed by an enzyme known as
ribonucleotide reductase (Scheme I). Enzymatic ribonucleotide reduction involves a free
radical mechanism, and four classes of ribonucleotide reductases are known, differing
from each other in their mechanisms of free radical generation. Three of these
ribonmcleotide reductases have been intensively investigated. 1
0 0
~O"// 0 -O // O
//
0 B/ 0R ibonuclotid 0
reductases
Hd5 'oH HO
B=A G,C, U
Scheme I Reduction of ribonucleotides to deoxyribonucleotides by the enzyne ribonucleotide
reductase.
The RNR isolated from bacteria grown under aerobic conditions is prototypical of
the Class I RNRs. This enzyme uses ribonucleotide diphosphates (RDPR) as the
substrates. It is composed of two homodimeric subunits, R1 and R2. The R2 subunit
contains a cofactor, which is composed of an unusual y-oxo-bridged diferric cluster
adjacent to a tyrosyl radical (.Tyr 122 in Escheri chic coli). The tyrosyl radical is essential
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for catalysis and is generated by the diferrous form of R2 in the presence of molecular
oxygen.
The RNR isolated from Lactcobc illus leich anniii (class II) requires adenosyl
cobalamin (Adocbl = coenzyme B 12) as a radical generated cofactor. These enzymes use
ribonucleotide triphosphate (RTPR) as substrate. RTPR is a single polypeptide (Mr = 76
[da), which catalyzes the conversion of nucleotide triphosphates (NTPs) to 2'-
deoxynucleotide triphosphate (dNTPs) with concomitant oxidation of two active site
thiols to disulfides.
The RNRs isolated from E. coli grown under anaerobic conditions (class III) is
distinct from the enzyme produced under aerobic conditions (class I). When isolated it is
proved to have an essential glycyl radical which is generated by the second subunit of the
enzyme that is equivalent to R2 in the aerobic E. col RNR. The activating enzyme
requires S-adenosylmethionine and an iron-sulfur cluster to generate the glycyl radical
via a novel mechanism.
The RNR from Brevibacteriium i anunoniacgenes (which is considered as class IV)
has been recently characterized. It is thought to possess 1O3 subunit structure and a
dinuclear Mn3 cluster analogous to the diferric cluster of aerobic E.coli RNR. This class
of enzymes is poorly understood.
Despite the dramatic differences in these reductases (Fig. 5),10 their mechanisms
for IIuloitide red htion ('it least for clss I-Il) are similar and unsual, involving
exquisitely controlled radical base chemistry. Each of the metallo-cofactors initiates these
radical-dependent nucleotide reduction processes by generating a transient protein
radical. The working model is based on the two best-characterized RNRs, those from E.
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coli and L. leichInmiannii. The tyrosyl radical (in E. coli) and the adenosylcobalamin radical
(in L. leichni annii) has the same function: generation of the thiyl radical.("
E. Coli, mammalian L. leichimannii
/ " CH 2Ad
Co
Fe Fe
Class 1 S Class II
anaerobic E. coli
HO H
Thiyl
B. t-unnomiagenes radical N
-J H 0
-x?
S-adenosylethionine
Mn' Mn FeS cluster
Class IV Class III
Figure - The cofactors used by the four major classes of RNRs.
Work in this dissertation was correlated with the mechanism of the ribonucleoside
diphosphate reductas (RDPR) of E. coli since it closely resembles the mammaan
ribonucleotide reductases. The diferric-tyrosyl radicals required by class I RNRs are
potentially attractive targets for the design of antitumor and antiviral agents.
1.2.1. STRUCTURE OF RDPR FROM Escherichia coli:
The enzyme system for dNDP formation consists of four proteins, two of which
constitute the ribonucleotide reductase, an enzyme of the 2 2 type. The other two
6
proteins, thioredoxin and thioredoxin reducta se, function in the delivery of reducing
equivalents. The two proteins of ribonucleotide reductase- are designated R1 and R2
and each is a homodimer in the haloenzyme (Fig. 6 ).1
R2 Fe Fe
R2
ATP,dATP
binding site
R Cys439 controls
RI 35 A Ireactivity
dNTP allosteric
effector binding C
site controls Gu441 H SH
specihcity
Cys462 Cys225
Cys754 -SH
Cys759 SH
Figur 6 Ribonucleotide reductase class I
The RI homodimer carries two types of regulatory sites in addition to the
catalytic site. Purine and pyrimidine diphosphate substrates bind at the catalytic site. One
regulatory site, the substrate specificity site, binds the dNTPs and ATP, and the identity
of the nucleotide bound there determines which nucleoside diphosphate is reduced at the
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catalytic site. If ATP is in the substrate specificity site, ribonucleotide reductase
preferentially binds pyrimidine nucleosides at its active site and reduces them. With
dTTP in the specificity-determining site, GDP is the preferred substrate. When dGTP
binds to this specificity site, ADP becomes the favored substrate for reduction. The other
regulatory site, the overall activity site, binds either the activator ATP or the negative
effector dATP. If ATP is bound, the enzyme is active, while if its deoxy counterpart,
dATP, occupies this site, the enzyme is inactive. In addition, it also contains the five
cysteines that are essential for catalysis. The dithiol pair (Cys462/Cys225) deliver the
reducing equivalent at C2' while Cys754/Cys759 reduce the resulting disulfide to the
dithiol pair required for next catalytic cycle' " 3
The two Fe atoms within the single active site by the R2 homodimer generate the
Tyr122 free radical required for ribonucleotide reduction on a specific R2 residue. The
Tyr122 radical in turn, generates a thiyl free radical (Cys-S-) on Cys439 on R1 unit." 'It
has been proposed that Cys439-Se initiates ribonucleotide reduction by abstracting the 3'-
H from the ribose ring of the nucleoside diphosphate substrate and forming a free radical
on C-3'. Subsequent dehydration forms the deoxyribonucleotide product."0
1.2.2. POSTULA TED MECHANISM OF ACTION OF RDPR:
Deoxyribonucleotides are formed by reduction of the corresponding
ribonucleotides. The 2'-hydroxyl group of the ribose is replaced by a hydrogen atom in a
reaction that takes place at the level of the ribonucleoside 5'-diphosphate. The mechanism
appears to be simple at first sight but it is in fact extremely complicated. The most
accepted mechanism proposed for a generic nucleotide reduction is shown in Scheme II.
s
439
S. SH SH
PPOB B 
a B
H H H
HO OH O-H 0 H
d 20
, H ,H H20
C02 SH SH c' S SH 0 2 H S SH
S SH SH
PPO PPO B B
HO H HO H H
02 S---S CO2 S -CO 2H S S
Sch em 11 Proposed nechanism for nucleotide reduction by RNRs.
The key steps involve cofactor-mediated formation of a transient thiyl radical
which initiates the nucleotide reduction process by abstracting the b-hydrogen atom from
the nucleoside diphosphate. H0 is lost,"L and the two cysteines on the u-face of the
nucleotide (Cys462, Cys225) deliver the required reducing equivalents, generating a Y-
ketodeoxynucleotide and a disulfide radical anion. This intermediate is subsequently
reduced to give dNDP and a disulfide, regenerating the thiyl radical. The essential
rIetallo-cofactor, the interactions between the two subunits of the class I RNRs and the
9
unusual radical intermediates in the nucleotide reduction process have all provided
proven targets for design of inhibitors of this essential enzyme.
1.2.3. ENZYME INHIBITION BY 2'-TIHIOURIDINE DIPHOSPHATE:
DNA synthesis depends on a supply of deoxyribonucleotides. These are found at
low levels within cells, and the enzymic reduction of ribonucleotides to
deoxyribonucleotides is thought to be a rate-controlling step in the biosynthesis of DNA.
The importance of ribonucleotide reductases in DNA synthesis has led to intensive
studies on the inhibition of this enzyme. The enzyme from Escherichia coli is the
prototype for all mammalian and viral ribonucleotide reductases. 2-Substituted 2'-dNDP
derivatives, as substrate analogs, have been shown to be very potent inactivators of this
enzyme, some of them with potential applications as anticancer drugs in clinics.
Furthermore, studies with these inhibitors have provided much insight into the enzyme
mechanism.
In 1976, Thelander and coworkers reported that 2'-chloro-2'-deoxynucleotides (X
= Cl) such as CICDP and 2'-azido-2'-deoxunucleotides (X = N3) such as N3UDP or
N3CDP were potent inactivators of RDPR 1 A detailed understanding of the mechanism
by which these compounds inactivate the enzyme has evolved since their discovery 10
In 1996, Fontecave and his group reported that 2'-deoxy-'-mercaptouridine 5'-
diphosphate, a substrate analog, was a very efficient inactivator of RDPR (K = M35 p
kinact= 0.18 s -) It was found that the inactivation was due to specific scavenging of
the protein R2 tyrosyl radical. During reaction, a transient organic radical was dectcted
by EPR spectroscopy. Its g anisotropy (;:= 2.0620, g = 2.0265, and g. = 2.0019) and its
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hyperfine structure were consistent wvith a perthiyl RSS- radical. The loss of the hyperfine
structure by deuterium labeling of the protons of RI cysteines unambiguously showed
that the perthiyl radical was located on protein R1. This unique feature set this compound
apart from those mechanism-based inhibitors such as 2'-azido- or 2'-chloro-2'-
deoxyribonucleotide which induce partial or total protein R1 inactivation. These results
allowed the formulation of a third type of mechanism for the inhibition of RDPR by 2'-
deoxy-2'-mercaptouridine 5'-diphosphate (Scheme 111).1
S" S.
PPOB B
H H
HO SH HO S
SH SH SH S
SH SH
PPOB B
H
/
0 H HO S
/S.\
SH S SH S
Scheme III Proposed nechanism- based inactivation of RDPR by 2'-deoxy-2'-
nercaptouridine 5'-diphosphate.
I1
Upon binding of '-deoxy-2-mercaptouridine 5'-diphosphate to the active site of
RDPR, a mixed disulfide is generated, coupling the sulfur atom of the substrate to the
cysteine (462 or 225) of R1, in the presence of oxygen. Cys439 thiyl radical, generated at
the expense of the R2 tyrosyl radical as for the natural substrate, abstracts the 3-hydrogen
of the mixed disulfide intermediate. In the absence of oxygen, no disulfide is formed
explaining why no loss of tyrosyl radical could be observed.
The next step is proposed to be the homolytic cleavage of the '-carbon-sulfur
bond, releasing a 3'-keto derivative and generating the perthiyl radical observed by EPR
spectroscopy. The tyrosyl radical cannot be regenerated during reaction of the perthiyl
radical with protein R2, thus explaining the inactivation of R2. The formation of the
perthiyl radical requires that the active site cysteines of RI be in the reduced form. If they
are oxidized or changed to serines, the tyrosyl radical disappears as expected, but no
perthiyl radical could be observed. It was observed that mutation of cys439 to serine
totally blocks the electron transfer.
1.3. CHEMICAL PREPARATION OF DEOXYNUCLEOSIDES FROM
NUCLEOSIDES. RADICAL EOXYGN AT ON
Ribonucleosides, as their 5'-di- or triphosphates, are biosynthetically converted to
their 2'-deoxy counterparts by ribonucleotide reductases. These completely retention-
stereoselective free radical mediated deoxygenations utilize a complex sequence of
enzymatic reactions and cofactors to provide the sole the novo pathway to the DNA
components' From the chemical point of view, many different methodologies have been
employed for the preparation of deoxynucleosides and/or deoxynucleotides. 2'-
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Deoxygenation of ribonucleosides has been pursued for many years with variable
success. Regiospecific 2'-deoxygenation of ribonucleosides has been impeded by the
difficulty in differentiating the secondary cis 2' and 3' hydroxyl groups. In 1983 a general
procedure for the efficient deoxygenation of secondary alcohols was reported.24
Regioselective protection of adenosine I with I,1,3,3-tetraisopropyl-1,3-disiloxanediyl
chloride (TPDS) gave the 3',5'-O-TPDS-nucleoside 2. Phenoxythiocarbonylation (PTC)
of the '-hydroxyl group of the protected compound, AIBN-initiated homolytic
deoxygenation with tri-n-butyltin hydride, and deprotection with tetra-n-butylammonium
fluoride completed the conversion of ribonucleosides to 2'-deoxyribonucleosides 2c.
Overall, conversion yields ranged from 57 to 78% (Scheme IV).
N NH 2
O N NH 2  
N N
SN TPDSCI2
HO OH Si
1 2
PTCCI
N NH 2
N NH2  o No N
o N N Si-O NN
RD N-tz1
i AIBN/n-Bu 3SnD o bPTC(D) Si
RO D ~88% i n-Bu 4N+F
2 R = TPDS 2
2c R=H
S chee IV Regiospecilic and stereoselective conversion of ribonucleosides to 2'-
deoxyribonucleoside.
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Greater than 85% stereoselectivity on the deuterium transfer from the bulky
tributylstannane to the less hindered . (ribo) face for the 2'-deoxygenation of adenosine
derivatives,' reduced with tri-butyltin deuteride, in comparison with the complete
retention stereoselectivity executed by ribonucleotide reductase was found.
1.4. THE STEREOS ELECTIVITY OF RADICAL REACTIONS
In describing the stereochemical features of chemical reactions, we can
distinguish between two types: stereospecific reactions and stereoselective reactions. A
stereospecific reaction is one in which stereoisomeric starting material afford
stereoisomerically different products under the same reaction conditions. A
stereoselective reaction is one in which a single reactant has the capacity of forming two
or more stereoisomeric products in a particular reaction but one is formed preferentially.
The stereochemistry of the most fundamental reaction types such as addition,
substitution, and elimination are described by terms, which specify the stereochemical
relationship between the reactants and products.
The stereoselectivity of free radical reactions is an area of considerable current
interest v, 7 For example, it has been already pointed out that some additions are
with both groups approaching from the same side. The others are anti, with the groups
approaching from opposite sides of the double or triple bond during addition to carbon-
carbon multiple bonds. For cyclic compounds, there are further aspects of steric
orientation. In syn addition to an unsymmetrical cyclic olefin, the two groups can come in
from the more-hindered face or from the less-hindered face in the double bond.
Electronic effects can also play a part in determining which face is attacked. Studies on
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five- and six-membered ring radicals as well as on vinylic radical systems have clearly
demonstrated the dominance of steric influences of vicinal substituents in determining the
facial anti-selectivity. In the case of hydrogen transfer reactions the anti- or syn-
selectivity of the incoming hydrogen, or deuterium, is determined by the stereochemistry
of the starting material or according to the position of a specific substituent on the
molecule. 5
.4.1. EFFECT OF VICINAL FLUORINE ON RADICAL REACTIONS
Alkyl radicals are generally pyramidal, although the inversion barrier is very
small. They can however, have rigid pyramidal or planar structures. It has been suggested
that two factors are of principal importance in favoring a pyramidal structure. One is a
torsional effect in which the radical center tends to adopt a staggered conformation of the
radical substituents. There is also a hyperconjugative interaction between the half-filled
orbital and the hydrogen that is aligned with it. This hyperconjugation is stronger in the
conformation in which the pyramidalization is in the same direction as to minimize
eclipsing.
R dical geometry is also significantly affected by substituent groups that can act
as 7T donors. Addition of a fluorine substituent favors a pyramidal structure. It has been
reported that there is a repulsive interaction between the singly occupiedp orbital and the
filled orbitals occupied by "lone-pair" electrons on the fluorine substituent. This repulsive
interaction is minimized by adoption of a pyramidal geometry. 2
There have been many studies aimed at deducing the geometry of radical sites by
examining the stereochemistry of radical reactions. A planar or rapidly inverting radical
15
would lead to racemization, whereas a rigid pyramidal structure should lead to product of
retained configuration. Cyclic molecules permit deductions about stereochemistry
without the necessity of using resolved chiral compounds.
Dolbier and Balberger observed anti-selectivity (77:23) in the reduction of -
fluorocyclopentenyl radicals with tributyltin deuteride (Scheme V): 8 They precluded
steric effects from having been the decisive factor in determining the stereoselectivity of
D-atom transfer. Influence of vicinal fluoro substituents on the diastereoselectivity of
radical reactions was attributed to the effect of anti- versus syn-pyrimidalization of
radicals in transition states. Marquez and coworkers reported that non-metal hydride
radical deoxygenation of nucleoside was favorably influenced by the presence of a -
fluorine.- f-oxygen effect on radical deoxygenation of thionocarbonyl esters has also
been examinated.'o
n-Bu 3 SnD F
F Br sH6  H
F D F D
23 : 77
Scheme V Reduction of p-IfLuorocyclopentenyl radical
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1.5. FLUORINATED NUCLEOSIDE ANALOGS
Nucleocidin (Fig. 7), one of the very few natural products containing a fluorine
atom, has been isolated from Streptoim,'ces calvus and is used as an antitrypanosomal
antibiotic. The fluorine atom is the most electronegative atom that can be introduced in
an organic compound and has a van der Waals radius (1.35 A) comparable to that of
hydrogen (1 17 A). Substitution of fluorine for hydrogen has a strong effect on the
electronic configuration of a molecule, often reflected by a dramatic change in biological
activity.
It is well established that the introduction of a fluorine atom at a sugar carbon in
nucleosides alters their biological activities toward various cellular, pathogenic, and
tumor-specific enzymes in various ways.33 For example, 3'-fluoro-2',3'-dideoxythimidine
was found to be a potent inhibitor of HIV-induced cytopathogenicity and 4'-fluorinated
carbocyclic nucleoside displays potent antiviral activity against Herpes sinlex viruses.
0
H % N HO NHO N
00 N F
H' 'bH HO F NH
N -fluoro-2',3- 2-ara-fluoro-4-fluoroNucleosidin
dideoxythimidine carbocyclic gunosine
Figure 7 Fluorinated nucleoside analogs
The replacement of a hydroxyl group by a fluorine atom causes only a minor
change in the steric effect of the functionality, but such a substitution has profound
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effects on the chemical properties. It also changes the stereoelectronic properties, which
result in specific overall conformational change of the fluorinated nucleosides. The strong
gauche effect of the fluorine substituent (due to its high electronegativity) has a profound
stereoelectronic effect on the stereochemical orientation of the neighboring groups:
1.6. OBJECTIVE OF THE RESEARCH
Synthesis of 9-(2-thio---D-airabinofuranosyl)adenine 5'diphosphate 10 was
targeted in this study as potential inhibitor of ribonucleotide reductases. The arabino 2'-
mercapto group in inhibitor 10 might interact with crucial thiyl radical at cysteine 439,
which is hypothesized to initiate nucleotide reduction by abstraction of H3' from the
substrate ribonucleotide. Such interaction between these two thiols may lead to the
inhibition of RDPR via formation of the RI Cys439-2'-mercapto disulfide bridge.
Competitive abstraction of hydrogen from the 2'-thiol function rather than regular
abstraction of 13' by Cys439 have to be considered as an alternative inhibition pathway
(Scheme VI). It is noteworthy that homolytic bond dissociation energies of 91 kcal/mol
for S-H and 94 kcal/mol for H-C-O make hydrogen atom abstraction from 2'-thiol
thermodynamically more feasible:
However, bindingy attributes including conformation of the synthesized molecule
at the active site of the enzyme might either favor or exclude such interaction from the
stereochemical point of view.
The arabino thionucleotide can also serve as a valuable probe for understanding
the role of the cysteinyl 439 radical during enzymatic deoxygenation with natural
substrates. It is also well known that arabino nucleoside analogs are very potent,
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clinically approved, anticancer agents. Therefore, the synthesized thionucleosides are
being evaluated against various cancer lines.
In order to evaluate steric and stereochemical flexibility of disulfide analogs for
binding at the active site of the enzyme, synthesis of the corresponding arabino methyl
disulfide and the ribo n-propyl disulfide derivatives (15 and 22 respectively) was also
targeted during this work.
SH S Abstraction SH
{ B O H B of H from2 0 B
PPO H S Tyr122 PPO H S thiol group PPO H S
HO H HO HO
SH SH SH SH SH SH
Covalent
1 inhibition of Abstraction
the enzyme of 3'H
S SH
O B B
PPO S PPO SH
H H S
HO H HO
SH SH SH SH
Sc he VI A possible inhibition of RDPR by 9-(2-thio--D-arabinofura nosyl) adenine
5' diphosphate.
Preparation of 2-deoxy-2-fluoroadenosine 3 and its arabino epimer 37 as well as
3'-deoxy-3'fluoralenosine 36 and its xylo epimer 38 was the second target on this
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project. Stereoselectivity of deuterium incorporation during radical deoxygenation was
determined in order to study the electronic versus steric -fluorine effects on all of these
fluorine containing pentofuranose nucleosides.
Incorporation of deuterium into the sugar moiety of compounds under study was
followed by H' NMR analysis of signals for HI2,2" or H3 3" depending on the case.
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2. RESULTS AND DISCUSSION
2.1. SYNTH ESIS OF SULFUR MODIFIED COMPOUNDS
2.1.1. SYNTHESIS OF 9-[2-DEOXY-2-ALKYLDIfTHIO--D-
ARABINOFURANOSYL]ADENINE
Incorporating a thiol function in nucleosides, nucleotides, and oligonucleotides
and preparing their stable precursors is of interest in the search of bioactive compounds.'
Mixed disulfides have been found to be interesting precursors that could be reduced
efficiently and rapidly under mild conditions for generating the active species." A
literature search revealed that different methods have been developed in this regard:
From the available thionucleosides,) purine 2'-mercapto analog 4 " 6 was chosen
because attempts to synthesize 1-(2-thio-p-D-arabinofuranosyl)uracil failed due to the
rapid Michael addition of arabiio 2'-mercapto function across the double bond of the
uracil moiety to give 2'-deoxy-2', 6-epithio-5, 6-dihydro derivative.
Selective 3,5-0-protection of adenosine4 (1) was achieved by employing
Markiewicz-Wiewiorowski reagent 1,3-dichlor-o-1,1,3,3-tetraisopropyldisiloxane
(TPDSCI,) to give 2. Activation of the hydroxyl group at carbon 2' of the silyl protected
compound with N-Phenyltrifluor-omethanesulfonimide [(CFSO ),NC(H j in the presence
of dirmethylaminopyridine (DMAP) gave 3',5'-0-[1,1,3;3-
tetraisopropyldisiloxane(TPDS)-1,3-diyl]-2'-O-(trifluoromethanesulfonyl)adenosine" 3 in
79% yield.
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In a first approach for the preparation of a mixed disulfide, nucleophilic
substitution of the triflate group on compound 3 by a thioacetate has been investigated.
Thus, treatment of 3 with potassium acetate gave arabino epimer 4 of the protected 2'-S-
acetyl-2-thioadenosine.
Sequential removal of the 3',5'-O-TPDS [(tetrabutylammonium fluoride (TBAF)]
and 2'-S-acetyl (NH3/MeOH) groups afforded 9-(2-thio- -D-arabinofuranosyl)adenine (6;
15-30%) after purification on a Dowex I X 2-200 anion-exchange resin (OH~)
column 40 Careful mild treatment of 4 with TBAF effected selective desilylation to
give 2'-S- acetyl-6 as a m jor product in addition to a small amount of 6, after separation
on silica gel column (Scheme IV). The 2'-mercapto compound 6 had spectroscopic data
as reported but slow forration of the corresponding disulfide was apparent since the
treatment of the mixture with dithiothreitol (DTT) lead to a much sharper peak on TLC.
The mixed disulfide 8 with a propyl side-chain was prepared from 6 using diethyl
azodicarboxylate (DEAD) as a oxidizing agent in the presence of propanethiol7 4 Thus,
treatment of 6 with DEAD and 1-propanethiol in THF gave disulfide 8 (-35%) plus
unchanged 6 (~20%). In order to overcome solubility problems which significantly lower
the yield, compound 4 was treated with NH/MeOH to give 9-(3,5-0-TPDS-2-thio--D-
arabinofuranosyl) d enine (7) in quantitative yield. Treatment of 5 with
DEAD/C HSH/THF gave protected disulfide 7 (75%) but separation from the diethyl
hydrazinedicarboxylate byproduct was tedious. Desilylation (NH 4F/M eOH)46 gave 8
(60%) which was readily purified. The characteristic signals for the propyl group (CH,-
CH -CH,-S-) were observed in 'H (0.88, 1.53, 2.57 ppm) and "C (121, 22.0, 41.0 ppm)
NMRs of the disulfides 7 and 8.
In the second approach, recently developed chemistry utilizing 2'-[2-
(trimethylsilyl)ethane]thiol group1 was employed for the attempted preparation of the
stable disulfide precursors. Thus, displacement of the triflate from 3 with 2-
(tiimethylsilyl)ethianethiolate in DMF proceeded smoothly at 60 "C to give 2'-S-[(2-
trinethylsilyl)ethyl]-2-thionucleoside 12 in good yield (Scheme VII).
Schem VII
N NH 2  N NH2
HO N N N N
HO bH SiO OH
1 2
N NH2  b N NH2
0 N N h N N
RO N-" h S N
RO SC 2H4 SiMe 3  Si' OTf
12 R = TPDS 3
e 13 I=I
N NH2
O N NH2  -O O
RSHf ROS
RO N - - - - - -
_- SR RO SR
RO S
7 7 R= IPDS, R'=Pr 4 R=TPDS, RAc
R =H R'=Pr d R=TPDS, R'=H e,d
g 14 =TPDS,R'=Me 6R=H,R'H
1 R=HR'=Me
" Key: (a) TPDSCI j/pyridine; (b) CH Cl/N-phenyltrifluoron-ethanesu.lfonimide/DMAP;
(c) CH 3COSK/DMF; (d) NH3/M eO; (e) TBAF/THF; (I) DEAD/PrSH or MeSHTF;
(g) NH 4 F/MeOH; (h) Me SiC HS /KCO3/DMF; (i) (CH 3)2S,/(CI3)2S(SCH H)BF4/THF
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Deprotection of 12 with TBAF gave 13 showing stability of 2-
(trimethylsilyl)ethyl group towards fluoride." However, reaction of 12 or 13 with
dimethyl(methylthio)sulfonium tetrafluoroborate37,11 in the presence of large excess of
dimethyl sulfide failed to produce methyl disulfide derivatives of type 14 or 15. Instead,
unchanged 12 or 13 and a fluorescent byproduct(s) were isolated from the reaction
mixtures indicating instability of the purine ring (as opposed to pyrimidine)637 under
reaction conditions.
2.1.2. PREPARATION OF 9-[2-DEOXY-2-PROPYLDITHIO--D-
Al ABINOFURANOSYL]ADFNINE 5'-DIPHIOSPHA TE
From the methods available for the 5'-phosphorylation of nucleosides ' we chose
Poulter's methodology' which is based on the displacement of the 5'-O-tosylate ester
with the corresponding pyrophosphate ion. Thus, disulfide 8 was converted to a 5'-0-
tosylate 9 using standard chemistry with a bulky propyl group allowing selective 5'-
tosylation. Treatment of 9 with tis(tetrabutylanmonium) hydrogen pyrophosphate''
CHCN effected substitution to give 5'-diphosphate 10 (Scheme VIII). The ammonium
salt of the nucleotide was purified by ion-exchange chromatography on DEAE Sephadex
A-25 (HCO;-) using linear gradient of triethyl ammonium bicarbonate (TEAB, 0.05
0.50 M) as elutant. The "P NMR spectrum showed two doublets ( = 23.5 Hz) at 6 -
9.75 and -5.26 ppm, diagnostic for two phosphorus atoms, and 'H NMR spectrum
confirmed the structure. This material was converted to sodium salts by passing it
through a Dowex 50 (Na') column.
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"Key: (a) TsCl/pyridine; (b) (Bu 4N) HP1O 7/CHCN; (c) DTT/HO
Reduction of diphosphate 10 with slight a excess of DTT immediately generates'
the corresponding thiol 11 as observed by TLC and MS. Dithiothreitol was chosen as a
reduCin agent since it is one of the electron sources used in the assays for ribonucleotide
reductase activity in vitro.
2.1.3. SYNTHESIS 0F OTHER ANALOGS
In addition to 9-[2-deoxy-2-propyldithio-f-D-arabinofuranosyl]adenine 8, the
corresponding methyl disulfide analo( 15 and the n-propyl ribo-derivative 22 were also
obtained. These compounds were prepared in order to evaluate steric and stereochemical
flexibility of disulfides analogs for binding at the active sites of the enzyme.
The methyl disulfide 15 was obtained by treatment of the thiol 6 with
MeSH/DEAD/THF using the same procedure as described for 8 (Scheme VII). Synthesis
of the propyl disulfide 22 started from 9-( -D-arabinofuranosyl)adenine 16 and involved:
Markiewicz 3'5O'-0-protection, triflate activation (02') towards nucleophilic substitution,
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displacement of triflate group by thioacetate with inversion of configuration, and
deacetylation to give ribo-thiol 20. Treatment of the latter with PrS /DEAD/THE and
desilylation gave 2 (Scheme IX).
Schen IXN
N NH2
N N SN N N
HO N
SIC OR
H OH 2
16
~ 17 R =H
b 18 R= Tf
N NH 2  c N NH2
N SiON N
RO N-N N--
S 5 e S
R 'S /-- - SiQ SR
2 3
21 R= TPDS 19 R= Ac2 R=H d 20 R=H
"Key: (a) TPDSCI/pyridine; (b) CH2C/N-phenyltrifluoromethanesulfonimide/DMAP;
(c) CHCOSKIDMF; (d) NH/Me OH; (e) DEAD/PrSH; (f) NI4F/MeOH
2.1.4. SYNTHESIS OF 2,6-IISUBSTITUTED PURINE THIONUCLEOSIDES
Other 2,6-disubstituted-purine thionucleoside have been designed and
synthesized, using the same methodology presented above, to evaluate as anticancer
analogs. Thus, 2,6-diamino- (a), 2-amino-6-methoxy- (b) and 2-amino-6-chloro-9-(2-
deoxy-2-propyldithio- -D-arabinofuranosyl)purrine (c) were prepared from the
corresponding commercially available 2,6-amino-, 2-amino-6-methoxy- and 2-amino-6-
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chlor -9-(-D-arabinofuranosyl)purine, respectively (Scheme X). The synthesis was
performed in collaboration with Dr. Elzbieta Lewandowska.
Scheme X
x x
N_ N-
H2N- N H2N s N
N / Multi-steps N /
0 N 0 N
HO HO
HO OH HO S
Series: a X=NH,; b X=OCH 3; c X=C1
It has to be pointed out that the disubstituted analogs can be converted in vivo and
in vitro to the corresponding guanosine derivatives by the action of adenosine deaminase.
Therefore, they can be considered as possible pro-guanosine inhibitors. Guanosine
derivatives are much more difficult to manipulate and synthesize in the laboratory.
2.2. SYNTHESIS OF FLUORINE MODIFIED COMPOUNDS
2.2.1. PREPARATION OF 2'-DEOXY-2'-FLUO OADENOSINE AND 3'-DEOXY-
3'-FLUOROADENOSINI
For our synthetic purposes we were interested in a shorter route to the 2'-deoxy-2'-
fluoroadenosine 35 and its arabino epimer 37 as well as 3-deoxy-3-fluoroadenosine 36
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and its xylo epimer 38. Taking advantage of the control of conformation by bulky
protecting groups, Pankiewicz and his coworkers reported 0 5 1 an excellent method for
fluorination of ribonucleosides at the C2'- position. Thus, treatment of 3',5'-di-0-trityl-
adenosine 23 and 2',5'-di-O-trityladenosine 24, obtained after tritylation of adenosine 1,
with (diethylammino)sulfur trifluoride (DAST) gave 33 and 34 (Scheme XI).
Detritylation with trifluoroacetic acid afforded compounds 37 and 38, respectively in
moderate overall yield.
Scheme Xa
N NH 2  N NHTr N NHTr
HO 0  N N T N N T N NHN-TrO N- TrO
a +
Ho bH TrC bH Ho QTr
1 23 24
b N NHR b N NHR
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RO N RON-
R? F F bR
33 R=Tr 3 RTi
c 37 R= f1 38 R=H
"Key: (a) Trityl chloride/pyridine; (b) DAST/CHCl2/pyridine; (c) CF;COOH/CHC13 1:9
On the other hand, inversion of the 2 and 3'-hydroxyl groups in trityl-protected
adenosines 23 and 24 was performed via 0-triflyl derivatives 2 and 26. Subsequent
substitution with sodium acetate produced inverted esters 27 and 28. Treatment with
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MeOH/NH effected deacetylation to give the arabino- 29 and xyloderivatives 30.
Fluorination with DAST, induced a second inversion of configuration, to give 2'-ribo-
fluoro 31 and 3'-rbo-fluoro 32 in good synthetic yields. Detritylation afforded 35 and 36,
respectively (Scheme XII).
Scheme XI a
N NHTr N NHTr N NHR
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TrO N TrO N Nd RO N N
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a 26R=Tf c- 3 R = H 36R=H
a Key:(a) CF 3SO 2CVDMAP/CH CL; (b) AcONa /DMF; (c) MeOH/NH3;
(d) DAST/pyridine/dichlorom thane; (e) CF 3 COOH/CHC 3 1:9.
2.2.2. SYNTHESIS OF PHENOXYTHIOC ARONYL PRECURSORS OF
DEOXYF LUOIONUCLEOSIDES
Regioselective silylation (05') of the fluoro nucleosides 35, 36, 37, and 38 with
tert-butyldirnethylsilyl (TBDMS) chloride in DMF in the presence of imidazole produced
39, 40, 41, and 42. Treatment of 39 with phenoxythiocarbonyl (PTC) chloride2 gave 5'-
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O-BDMS-3'-O-PTC-2'-fluoro-2'-deoxyadenosine 43. Analogous treatment of 41
afforded the fluoro-arabino epimer 45 (Scheme XIII). The Y-fluoro isomers 40 and 42
were converted to 5'-O-TBDMS-2'-O-PTC-3'-fluoro-3'-deoxyadenosine 44 and its fluoro-
xylo epimer 46, respectively (Scheme XIV), completing the synthesis of all four fluoro-
isomer models.
Scheme XIIW
N NH 2  N NH 2
N N N / N
RO N b TBDMO O N N
HO Y PTCO x
a L:~ 35X=H,Y=F,R=H
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41X=F, Y=H, R=TBDMS
'Key: (a) TBDMSCl/imidazole/DMF; (b) PTCCI/DMAP/CH3CN
Scheme XIV"
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Key: (a) TBDMSCl/imidazole/DMF; (b) PTCCI/DMAP/CH3CN
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A FLUORINE SUBSTITUENT ON RADICAL DEOXYGENATION
Treatment of 3'-PTC ester 43 with tributyltin deuteride effected deoxygenation to
give 5'-O-TBDMS-2',3'-dideoxy-3'-deuterio-2'-fluoroadenosine epimers 47 (3 RIS,
64:36). On the other hand, reduction of 3'-PTC ester 45 (fluorine up) gave the
corresponding 3'-deuterio epimers 49 (3' P/S, 93:7) (Scheme XV). The ratio of ribo/xylo
deuterium substitution (Table 1) was determined on the bases of vicinal coupling constant
analysis (3JF-1 and 3 H-H) in 'H NMR.
Scheme XV
TBDMN NH2  RN NH2
TBDMO 0 N RO N- Na
PTCO Y(D)H Y
47X=H, Y=F,R=TBDMS
43X=HY=F b 51X=H,Y=F,R=H
45X=F,Y=H b (49X=F,Y=H,R=TBDMS
53X=F ,Y=H,R=H
"Key: (a) Bu 3SnD/AIBN/toluene/85 C; (b) NH4F/MeOH.
Radical deoxygenation of 44 (fluorine down) gave 5'-O-TBDMS-2',3'-dideoxy-2'-
deuterio-3'-fluoroadenosine 48 (2' RIS, 14:86) as 2'-deuterio epimers. Analogous
treadment of 46 (fluorine up) effected reduction to give epimers 50 (2' P/S, 7:93) (Scheme
XVI). Radical deoxygenation was performed twice on all four phenoxythiocarbonyl
derivatives with all showing similar results to the NMR spectra that are presented in
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Table I as average values. Coupling constants are in agreement with the values mesured
and calculated by Chattopadhyaya and coworkers 4 for the 2',3'-dideoxy-3' (or 2')-
fluorouridine derivatives and for adenosine analog 54.
Scheme XVIa
N NH 2  N NH 2
O N N N- NR O N ~ a R O N ---
X 'OPTC X H(D)
b 48X=H,Y=F, R=TBDMS44X=H,Y=F,R=TBDMS 52X=HY=FR=H
46X=F,Y=H,R=TBDMS 50X=F, Y=H, R=TBDMS
b 54X=FY=HR=H
Key: (a) BU3SnD/AIBN/toluene/85 "C; (b) NH4 F/MeOH.
Table 1. The ratio for deuterium substitution during radical deoxygenation of 2'(or 3')0-
PTC derivatives of fluorine-containing pentafuranose nucleosides
2(3')-0-PTC-3'(2')- Ratio of 2'(3')-deuterio epimers Diastereotopic excess
fluoro precursors
43 47 (31 RS 64:36) 28
2'-fluoro-ribo anti/s yn 36:64
45 49 (3'R/S, 93:7) 86
2'-fluoro-arabino anti/isn, 93:7
44 48 ('R/S, 15:85) 70
3 '-fluoro-ribo anti/syn, 15:85
4650 (I, 793 ) 86
3'-f]Luoro-xylo anti/svn, )3:7
Duplicate samples were combined and deprotected. Thus, treatment of 47, 48, 49,
and 50 with NH4 / eOH afforded 51, 52, 3, and 54 respectively. The ratio of 2' (or 3')-
deuterio epimers for the deprotected fluoronucleosides was also determined and defined
as a ratio of ant!/s1n selectivity of deuterium substitution versus fluorine substituent
(Table 2).
Table 2. Ratio of 2' (or 3')-deuterio epimers for deprotected fluoronucleosides
2'(3')-dideoxy-3'(2')- Ratio of 2'(3')-deuterio epimers Diastereotopic excess
fluoro precursors
51 (3'R/S 64:36) 28
2'-fluoro-ribo anti/syn, 36:64
53 (3R/ S, 92:8) 84
2 f-luoro-arabino anti/syn 92:8
52 (TIS, 14:86) 72
3-fl uoro-ri bo anti/yn, 14:86
54 ('R/S, 7:93) 86
3 -fluoro-xylo anti/syn, 93:7
These results clearly indicate that although steric effect of the heterocyclic base is
the most decisive factor in determining stereoselectivity for deuterium abstraction by
pentafuranosyl radical, stereochemical position of vicinal fluorine also influences
stereoselectivity for deuterium incorporation. Thus, if fluorine has no significant steric
effect, stereoselectivity is enhanced for the anti delivery to vicinal fluorine substituent
(Schem XVII).
33
Scheme XVII
~N NH2  ~N NH2
o N N 
NBSTBDSO N 8 BDS
6asrato /F 
-abstractionF
antt Io esyll to fluorineF
a-astr ictio ctasrato
spz t tlu ineanti to fluoiine
43 
-~ 47 45 49
34
3. EXPERIMENTAL SECTION
3.1. GENERAL PROCEDURE
Melting points were termined with a capillary apparatus and are uncorrected.
UV spectra were measured in methanol using a Shimadzu UV-2101 PC scanning
spectrometer. 'H (Me4Si) at 400 MHz, '3C (Me 4Si) at 100 MHz 'P (H3PO4) at 162 MHz
and ''F (CCI3F) at 376.4 MHz NMR spectra were recorded at on a Bruker NMR
spectrometer with solutions in CDCI, unless otherwise specified. Mass spectra were
obtained by the atmospheric pressure chemical ionization (APCI) technique using a
Finnigan Navigator LC/MS and MeOH as a solvent. Evaporations were effected with
Buchi rotary evaporator using water aspirator or mechanical oil pump at < 35 C.
Elemental analyses were determined by Galbraith Laboratories, Knoxville, TN. Merck
silica gel 60-F?5 precoated aluminium sheets were used for thin-laver chromatogriaphy
(TLC) and products were detected with 254 nm light. Merck silica gel 60 (230-400
mesh) was used for column chromatography. Unless otherwise specified solvents used
for column chromatography and TLC were as follows: (SI) EtOAc; (S2) The upper phase
of EtOAc/i-PrOH/H20 (4:1:2); (S3) EtOAc/S2 (90:10); (S4) EtOAc/S2 (75:25); (S-)
30% Me-OH in S2; (S6) C-CL/MeOH (95:5); (S7) i-PrOH/NH 40H/H0 (3:1:1). Reagent
grade chemicals were used and solvents were dried by reflux over and distillation from
CaH under argon except THF (K/benzophenone). Sonification was performed with a
Branson 5200 ultrasonic bath. Ion exchanue chromatography was performed with
Sephadex-DEAE A-25, (40-120t), Dowex-50W-hydrogen and Dowex-1-chloride foam
(2/(, cross linking, 100-200 mesh) ion exchange resins.
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3.2. SYNTHESIS OF 2'-DISULFIDE ANALOGS OF ADENOSINE
3',5'- O-(1,1,3,3- Teraisopropyl-1,3-disiloxanediyl)adenosine (2). Procedure A
To 400 mg (1.5 mmol) of dried adenosine 1 suspended in 12 mL of pyridine was
added 480 ptL (474 mg, 1.5 mmol) of 1,1,3,3-tetraisopropyl-1,3-disiloxanediyl chloride.
The mixture was stirred at room temperature for 3 h, pyridine was evaporated and the
residue was partitioned between EtOAc and H0. The organic layer was washed with ice-
cold 5% HCl/H,0, saturated NaHCO/HO and NaCl/H,0, dried (MgSO4), filtered and
evaporated. The residue was column Chromatographed (EtOAc-+5% MeOH/EtOAc) to
give 2 ( 694.5 mg, 91%) with spectroscopic and physical properties as reported.'
2'-O-(Trifluoronethanesulfonyl)-3',5'- 0-(1,1,3,3-etr aisopropyl-1,3-
disiloxanediyl)adenosine (3). Procedure B
510 mg (1.0 mmol) of 2 and 4-dimethylaminopyridine (DMAP) (367 mg, 3.0
rmnol) were suspended in anhydrous CHCI, (5 mL) at 0 C. 428 mg (1.2 mmol) of N-
phenyltrifluoromethanesulfonimide were added to the cold solution and the reaction
mixture was stirred for 20 min. Solvent was evaporated and residue was partitioned (ice-
cold AcOHIH,O 1:9//CHCLa). Organic phase was washed with ice-cold saturated
NaHC O, and NaCl, dried (MgSO4) and evaporated. Residue was column
chromatographed (EtOAc/hexanes; 70:30) to afford 3 (507.3 mg, 79%): 'H NMR 6 1.03-
1.26 (m, 28, 4 X i-Pr), 4.03 (d, J = 13.3 Hz, 1, H5"), 4.11 (d, J = 9.3 Hz, 1, H4'), 4.20 (d,
J = 13.1 Hz, 1, H5'), 5.31 (dd, J = 4.7 Hz, 9.2 Hz, 1, H3), 5.82 (d, J = 4.7 Hz, 1, H2'),
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6.14 (s, 1, Hi'), 6.39 (br s, 2, NH ), 7.98 (s, 1, H2), 8.26 (s, 1, H8) and other data as
reported.>
9-[2-S-Acetyl-3,5-O-(1,1,3,3-tetraisopropyl-1,3-disiloxanedi l)-2-tio- D-
ar ainofuranosyl]adenine (4). Procedure C
CH COSK (434 mg, 3.8 mmol) was added to a solution of 3 (1.53 g, 2.38 mmol) in
dried DMF (10 mL) and the resulting mixture was stirred overnight at ambient
temperature. Volatiles were evaporated and the residue was partitioned
(EtOAc//NaHCO /H,0). The organic layer was washed (NaCIl/HO), dried (MgSO4),
evaporated and the residue was column chromatographed (EtOAc/hexanes; 70:30) to give
42 (1.01 , 75%): mp 68-76 "C; UV max 260 nm (F 15 100), min 233 nrm (c 6 200); 'H
NMR 6 0.80-1.30 (m, 28, 4 X i-Pr), 2.19 (s, 3, Ac), 3.99-4.08 (m, 2, H4',5"), 4.28 (dd, J
= 4.5 Hz, 12.5 Hz, 1, H5'), 4.59 (dd, J = 7.3 Hz, 10.3 Hz, 1, H2'), 5.06 (dd, J = 8.2 Hz,
10.0 Hz, 1, H3), 6.45 (d, J = 7.3 Hz, 1, Hi'), 7.95 (s, 1, H2), 8.29 (s, 1, H8); MS (APCI)
/z 568 (100, MH). Anal. calcd for CH 4 N0SiS (567.86): C, 50.76; H, 7.28; N,
12.33. Found: C, 50.39; H, 7.49; N, 11.82.
9-[3,5-0-(1,1,3,3-tetraisopropyl-1,3-disiloxanediyl)-2-thio- --
arabinofuranosyl adenine (5). Procedure D
A solution of 4 (241 mg, 0.43 mmol) in saturated NH;/MeOH (50 ml) at 0 "C was
stirred for 30 min at ~0 "C. Volatiles were evaporated, and the residue was column
chromatographed (CHCL/MeOH; 95:5) to give S [254 mg, 97%; contaminated ('H NMR)
with 0.5 equiv. of CH3CONH,]: mp 78-82 "C; UV max 261 nm (e 14 400), min 230 nm
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(E 3100); 'H NMR 6 1.02-1.19 (m, 28, 4 X i-Pr), 1.47 (d, J= 8.1 Hz, 1, SH), 3.87 (dd, J=
7.6 Hz, 9.7 Hz, 1, H2'), 3.91 (dt, J = 8.2 Hz, 2.8 Hz, 1, H4'), 4.07 (dd, J = 12.9 Hz, 2.7
Hz, 1, H5'), 4.24 (dd, J = 12.9 Hz, .8 Hz 1, H5), 4.62 (t, J = 8.9 Hz, 1, H3'), 6.12 (br s,
2, NH,), 6.42 (d, J = 7.1 Hz, 1, H1'), 8.14 (s, 1, H2), 8.35 (s, 1, H8); "C NMR 12.8-
17.9 (12, 4 X -Pr ), 48.7 (C2'), 61.4 (C5'), 75.7 (C3'), 84.2 (CT), 85.3 (C'), 120.1 (C5),
139.7 (C8), 150.2 (C4), 153.2 (C2), 155.9 (C6); MS (APCI) m/z 526 (100, MH'). Anal.
calcd for C~HN50 4Si S, (525.54): C, 50.28; H, 7.43; N, 13.33. Found: C, 49.91; H, 7.68;
N, 12.81.
9-(2-Thio- -D-arabinofuracnosyl)adenine (6)
Treatment of 4 (283 mg, 0.5 mmol) with TBAF (1 M solution in THF; 1 mL) in
THE (15 mL) at 0 "C for 30 min. followed by NH,/MeOH (10 mL; 2h, ambient
temperature) gave crude 6. This material was partitioned (EtOAc/HO) and the water
layer was chromatographed [Dowex I X 2 (OH-); H,O X 25% MeOH/H 2O) to give 9-(2-
thio- -D-arabinofuranosyl)adenine" [6; 89 mg, 55%; contaminated ('H NMR) by the
corresponding dimer-disulfide].
9-[3,5-0-(1,1,3,3-tetraisopropy -1,3-disioxanediy)-2-deoxy-2-propyIdithio--D-
ara binofuranosyl]adenine (7). Procedure E
A solution of 5 (370 mg, 0.7 mmol) and DEAD (113 tL, 0.72 mmol) in THF (7 mL)
was stirred overnight at ambient temperature and then propane4--thiol (3.68 mL, 3.09 g,
41 mmol) was added. Reaction mixture was refluxed for 8 h and volatiles were
evaporated. The residue was partitionated (NaCO3/H 20//EtOAc) and the organic layer
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was washed (NaCI), dried (MgSO 4), evaporated and column chromatographed
(EtOAc/hexane; 1:1) to give 7 (182 mg, 43%): mp 110-118 C (soften); UV max 261 nm
(E 7600), min 233 nm ( 1400); 'H NMR 6 0.94 (t, J= 7.4 Hz, 3, CH 3), 1.07-1.17 (m, 28,
4 5 i-Pr ), 1.62 (sextet, J= 7.4 Hz, 2, CH 2), 2.61 (t, J= 7.4 Hz, 2, SCH2), 3.91-3.97 (m, 2,
H2',4'), 4.05-4.10 (m, 1, H5',5'), 4.60 (t, J= 8.5 Hz, 1, H3'), 6.54 (d, J= 6.8 Hz, 1, H1'),
8.15 (s, 1, H2), 8.33 (s, 1, H8); MS (APCI) m/z 600 (100, MH+).
9-(2-Deoxy-2-propyldithio-P-D-arabinofuranosyl)adenine (8). Procedure F
NH4F (222 mg, 6.0 mmol) was added to a stirred solution of 7 (180 mg, 0.3 mmol)
in MeOH (25 ml). After 18 h, volatiles were removed in vacuo and the residue was
column chromatographed (CHC13/MeOH; 95:5) to give 8 (60 mg, 56%): mp 120-124 C
(dec.); UV max 261 nm (F 14 800), min 231 nm (c 5100); 1H NMR (MeOH-d4) 6 0.87 (t,
J= 7.3 Hz, 3, CH 3), 1.53 (sextet, J= 7.3 Hz, 2, CH 2), 2.57 (t, J= 7.2 Hz, 2, CH 2S), 3.86-
3.95 (m, 4, H2',4',5',5"), 4.53 (t, J= 7.6 Hz, 1, H3'), 6.58 (d, J= 7.1 Hz 1, H1'), 8.21 (s, 1,
H2), 8.44 (s, 1, H8); 13C NMR (MeOH-d4) S 12.13 (CH 3), 22.03 (CH 2), 40.96 (SCH 2),
60.22 (C3'), 62.54 (C5'), 71.94 (C2'), 84.92 & 85.32 (C4' & Cl'), 119.0 (CS), 140.79
(C8), 149.50 (C4), 152.68 (C2), 156.30 (C6); MS (APCI) m/z 358 (100, MH+). Anal.
caled. for C1 Hi N5O3S2-H2O (375.47): C, 41.59; H, 5.64; N, 18.65. Found: C, 42.21; H,
5.65; N, 18.27.
Treatment of 6 (160 mg, 0.56 mmol) with DEAD (98 mg, 0.57 mmol) and propane-
1-thiol (2.9 mL, 2.4 g, 32 mmol) in THF (15 mL), as described for 7, also gave 8 (35 mg,
17%).
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9
-[2 -Deoxy-2-propy ithio-5--(-toluenesulfonyl)-
P-D-arabinofuranosyl]adenine (9)
para-Tolylsulfonyl chloride (106 mg, 0.55 mmol) was added to a solution of 8 (40
mg, 0.11 mmol) in anhydrous pyridine (2 mL) and the reaction mixture was stirred for 3
h at 0 "C. Volatiles were evaporated, and the residue was partitioned
(NaHCO 3/H20//EtOAc). The organic layer was washed (AcOH/H2 O, NaHCO 3/H20),
dried (MgSO 4). Residue was evaporated and column chromatographed (EtOAc -+ 2.5%
MeOH/EtOAc) to give 9 (28 mg, 52%): 1H NMR 6 0.90 (t, J = 7.2 Hz, 3, CH 3), 1.56
(sextet, J= 7.2 Hz, 2, CH2), 2.42 (s, 3, PhCH 3), 2.59 (m, 2, CH 2S), 3.90 (t, J= 8.2 Hz, 1,
H2'), 4.16 (m, 1, H4'), 4.42 (dd, J= 11.2 Hz, 3.1 Hz, 1, H5'), 4.45 (dd, J= 11.3 Hz, 4.5
Hz, 1, H5'), 4.81 (t, J= 8.2 Hz, 1, H3'), 6.48 (d, J= 7.2 Hz 1, H1'), 7.27 (d, J= 8.0 Hz, 2,
Harom.), 7.87 (d, J= 8.1 Hz, 2, Harom,), 7.99 (s, 1, H2), 8.29 (s, 1, H8).
Preparation of Tris(tetra-n-butylammonium) hydrogen pyrophosphate
Method A. Tetrasodium pyrophosphate (1.11g, 2.5 mmol) was dissolved in
deionised water (10 mL). The dissolved salt was applied to a column of Dowex 50W 2-
200 (He) ion change resin (2% cross linking, 100-200 mesh, hydrogen form) and eluted
with deionised water (~30 mL). Acidic fractions (pH ~1.5) were collected and resulting
solution was neutralized (pH ~7.3) by dropwise addition of 40% (wt/wt) solution tetra-n-
butylammonium hydroxide in H20. The neutralized solution was evaporated to yield
viscous, clear syrup, which upon high vacuum drying gave a hydroscopic white solid (2.2
g, 98%).49 1H NMR (D20) 6 0.77 (t, J= 7.3 Hz, 3H), 1.20 (m, 4H), 3.02 (t, J= 8.3 Hz,
2H); 31P R (D20) 6 -6.67 (s).
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Note: Tetrasodium pyrophosphate can be substituted by disodium hydrogen
pyrophosphate to give tris(tetra-n-butylammnonium) hydrogen pyrophosphate (97%, yield)
with identical spectroscopic characteristics.
Method B. A 10%(v/v) solution of disodium hydrogenpyrophosphate (3.33g,
15.0 mrnol) in aqueous ammonium hydroxide (15 mL) was passed through a 2.5 cm x 7.0
cm column of Dowex 50WX2-200 ion exchange resin (2% cross linking, 100-200-mesh,
hydrogen form). The free acid was eluted with deionised water (100 mL) and the
resulting solution (pH ~1.5) was immediately neutralized to pH 7.3 with aqueous tetra-n-
butylammonium hydroxide. The resulting solution (approximately 150 ml total volume)
was dried by lyophilization to yield 13.1 g (97%) of a hydroscopic white solid.
9-(2-Deoxy-2-propyldithio- -D-arabinofuranosyl)adenine 5'-diphosphate (10)
Tris(tetra-n-butylammonium) hydrogen pyrophosphate (31 mg, 0.035 mmol) was
added to a stirred solution of 9 (12 mg, 0.023 mmol) in CH CN (0.5 mL) and stirring was
continued at ambient temperature for 72 h. Volatiles were removed in vacuo and the
residue was dissolved in water and was purified on an ion exchange resin [Sephadex-
DEAE A-25. 40-120/t gradient elution with triethylammonium bicarbonate (0.05 --+ 0.5
M)]. Appropriate fractions were evaporated, and the residue was dissolved in HO and
was converted to the sodium salt by passing the solution through a Dowex (Na*) column
to yield 10 (4 mg, 29%) as trisodium salt: 'H NMR (MeOH-d 4) 6 0.64 (t, J = 6.3 Hz, 3,
CH3), 1.27 (sextet, J = 6.5 Hz, 2, CHI), 2.32 (t, J= 6.7 Hz, 2, CHS), 3.88 (dd, J = 7.4 Hz,
8.8 z, 1, H2'), 4.03-4.07 (m, 1, H4'), 4.19-4.23 (m, 2, H5',5"), 4.49 (t, J = 8.3 Hz, 1,
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H3), 6.84 (d, J= 7.1 Hz 1, H1'), 8.11 (s, 1, H2), 8.33 (s, 1, H8); "P NMR 6 -9.75 (d, J=
23.5 Hz, 1, Pa), -5.26 (d, J= 23.5 Hz, 1, Pf).
Treatment of 10 (2 mg) with dithiothreoitol (2 mg) in HO (2 mL) gave 11 whose
structure was confirmed by MS (odor of PrSH released was immediately noticed).
9-[2-S-(2-Trimethylsilylethyl)-3,5-O-(1,1,3,3-te traisopropyl- 1,3-disiloxaned iyl)-2-
thio- -D-arabinofuranosyl]adenine (12)
2-(Trimethylsilyl)ethanethiol (0.1 mL, 90 mg, 0.7 mmol) was added to a stirred
suspension of 3 (371 mg, 0.6 mmol) and KCO; (276 mg, 2 mmol) in DMF (3 mL) at
armbient temperature, and the reaction mixture was heated at 60 "C overnight. Volatiles
were evaporated and the residue was partitioned [CHCL//NaHCO3/HO (ice-cold)]. The
organic layer was washed (NaCl/HO), dried (MgSO4), evaporated and column
chromatographed (EtOAc/hexanes; 1:1) to give 2 (108 mg, 30%): 'H NMR b -0.07 (s,
9H, SiMe,), 0.57 (dt, J = 5.2 Hz, 14.0 Hz, 1, CHH Si), 0.61 (dt, J = 14.0 Hz, 5.2 Hz, 1,
CIlHSi), 0.80-.31 (m, 28, 4 X i-Pr), 2.49 (dt, J= 5.6 Hz, 12.7 Hz, 1, SCHH,), 2.53 (dt,
J = 5.6 Hz, 12.7 Hz, 1, SCHBH), 3.72 (dd, J = 7.0 Hz, 9.7 Hz 1, H2'), 3.89 (dt, J = 7.9
Hz, 3.0 Hz, 1, H4'), 4.09 (dd, J = 2.8 Hz, 12.9 Hz, 1, H5"), 4.16 (dd, J= 3.2 Hz, 12.9 Hz,
1 H5'), 4.55 (dd, J = 8.3 Hz, 9.3 Hz, 1, H3), 6.50 (d, J = 7.0 Hz, 1, H1'), 8.08 (s, 1, H2),
8.32 (s, 1, H8); MS (APCI) m/l 626 (100, MH). Anal. calcd for C1H9N50SSiXHO
(644.07): C, 50.35; H, 8.29; N, 10.87. Found: C, 50.39; H, 8.11; N, 10.49.
Treatment (ambient temperature to ~45 "C, 2h to overnight) of 12 (97 mg, 0.16
mmol) [or 13 (27 mg, 0.07 mmol)] with dimethyl(methylthio)sulfonium tetrafluoroborate
(219 mg, 1.12 mmol) and dimethyl sulfide (0.72 mL, 496 mg, 8 mmol) in anhydrous THE
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(5 mL) gave recovered 12 or 13 (-20% to 80% depends on reaction conditions) plus
other byproduct(s).
9-[2-S-(2-Trimethylsilylethyl)-2-thio-$-D-arabinofuranosyl]adenine (13)
TBAF/THF (1M; 0.3 mL, 0.3 mmol) was added to a solution of 12 (50 mg, 0.08
mmol) in THF (2 mL) and was stirred for 2h at ambient temperature. Volatiles were
evaporated and the residue was column chromatographed (EtOAc 8% MeOH/EtOAc)
to give 13 (27 mg, 90%): H NMR 6 -0.08 (s, 9H, SiMe3), 0.59-0.63 (m, 2, SiCH2), 2.40-
2.45 (i, 2, SCH2), 3.74 (dd, J = 6.9 Hz, 8.8 Hz 1, H2'), 3.80-4.01 (in, H4',5',5"), 4.32-
4.38 (m, 1, H3'), 6.57 (d, J = 6.9 Hz, 1, H1'), 8.20 (s, 1, H2), 8.41 (s, 1, H8); MS (APCI)
/z 384 (100, MHW).
9-[3,5-0-(1,1,3,3-Tetraisopropyl-1,3-disiloxanyl)-2-deoxy-2-methyldithio-0-D-
arabinofuranosyl]adenine (14)
A solution of 4 (100 mg, 0.19 mmol) and DEAD (29.1 L, 0.19 mmol) in THF (5
mL) was stirred overnight at ambient temperature and then methanethiol (183 mg, 3.8
mmol) in THF (3 mL) was added. Stirring was continued in a pressure Ace glass at
ambient temperature for 96 h, and then volatiles were evaporated and the residue was
column chromatographed (EtOAc/hexane; 1:1) to give 14 (40.6 mg, 37%): 'H NMR
6 1.04-1.14 (m, 28, 4 X i-Pr ), 2.32 (s, 3, SCH), 3.92-3.99 (m, 2, H2',4'), 4.05-4.21 (m, 2,
H' 5"), 4.76 (t, J= 7.8 Hz, 1, H3'), 6.07 (brs, 2, NH), 6.53 (d, 1, J= 7.1 Hz, 1, H1'), 8.01
(s, 1, H2), 8.33 (s, 1, H8); MS (APCI) n7/z 572 (100, MH').
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9-(2-Deoxy-2-methyldithio- -D-arabinofuranosyl)adenie (15)
Treatment of 14 (19 mg, 0.033 mmol) by procedure F gave 15 (7.3 mg, 67%):
UV max 261 nm ( 12 700), min 230 nm (E 2800); 'H NMR (MeOH-d) 2.33 (s, 3,
CH 3S), 3.87-4.00 (in, 4, H2',4',5',5"), 4.57 (t, J = 7.7 Hz, 1, H3'), 6.57 (d, J = 7.0 Hz 1,
Hi'), 8.20 (s, 1, H2), 8.39 (s, 1, H8); MS (APCI) mx/z 330 (100, MH); Anal. calcd. for
CH N0; 0.5 EtOAc (373.45): C, 41.85; H, 5.13; N, 18.75. Found: C, 41.47; H, 5.38;
N, 18.26.
9-[3,5- O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-f-D-arabinofuranosyl]adenine
(17)
Treatment of 9-(f-D-arabinofuranosyl)adenine 16 (267 mg, 1.0 mmol) by
procedure A afforded 17'4 (380 mg, 77%): 'H NMR 6 0.9-1.3 (m, 28, 4 X i-Pr), 3.85 (dt, J
7.7 Hz, 2.6 Hz, 1, H4'), 4.02-4.13 (m, Hi 5")4, 4.54 (t, J= 7.7 Hz, 1, H3'), 4.65 (t, J
= 7.0 Hz, 1, H2'), 6.23 (d, J = 6.0 Hz, 1, HI'), 8.09 (s, 1, H2), 8.14 (s, 1, H8).
9-[2-O-(Trifluoromethanesulfonyl)-3,5- O-(1,1,3,3-tetraisopropyl-1,3-disiloxanediyl)-
$-D-arabinofuranosyl]adenine (18)
Treatment of 17 (380 mg, 0.76 mmol) by procedure B gave 184 (360.6 mg, 75%);
'H NMR 60.99-1.23 (m, 28, 4 X i-Pr), 3.95-3.99 (m, 1, H4'), 4.09 (dd, J=12.36 Hz, 3.13
Hz, 1, H5"), 4.24 (dd, J = 12.31 Hz, 6.03 Hz, 1, H5'), 5.40 (t, J = 6.9 Hz, 1, H3'), 5.49 (t,
J= 6.4 Hz, 1, H2'), 6.42 (d, J= 6.1 Hz, 1, H1'), 7.95 (s, 1, H2), 8.30 (s, 1, H8).
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2'-S-A cetyl-3',5'-O-(1,1,3,3-tetraisopropyl-1,3-disiloxanyl)-2-thioadenosine (19)
Treatment of 18 (290 mg, 0.45 mmol) by procedure C gave 19 (200 mg, 78%): 'H
NMR 1.05-1.12 (m, 28, 4 X i-Pr), 2.31 (s, 3, Ac), 4.02-4.09 (m, 3, H4',5',5"), 4.70 (dd,
J = 7.4 Hz, 4.8 Hz, 1, H2'), 5.26 (dd, J = 7.2 Hz, 5.4 Hz, 1, H3'), 6.07 (d, J = 4.8 Hz, 1,
H1'), 7.97 (s, 1, H2), 8.29 (s, 1, H8); MS (APCI) n/z 568 (100, MH+).
3',5'-O-(1,1,3,3-tetraisopropyl-1,3-disiloxanyl)-2'-thioadenosine (20)
Treatment of 19 (180 mg, 0.31 mmol) by procedure D gave 20 (160 mg, 96%): 'H
NMR 6 1.03-1.15 (m, 28, 4 X i-Pr), 2.19 (d, J = 6.4 Hz, 1, SH), 4.08 (d, J = 4.7 Hz, 1,
H2'), 4.17-4.25 (m, 3, H4',5',5"), 4.88 (t, J = 6.4 Hz, 1, H3'), 5.98 (d, J = 7.1 Hz, 1, H1'),
6.22 (br s, 2, NH2), 8.01 (s, 1, H2), 8.34 (s, 1, H8); MS (APCI) ni/z 526 (100, MH).
3',5'-O-(1,1,3,3-tetraisopropyl-1,3-disiloxanyl)-2'-deoxy-2'-propyldithioadenosine
(21)
Treatment of 20 (140 mg, 0.27 mmol) by procedure E gave 21 (67 mg, 42%): 'H
NMR 60.89 (t, J = 7.3 Hz, 3, CH3), 1.07-1.12 (m, 28, 4 X i-Pr), 1.59 (sextet, J = 7.2 Hz,
2, CH 2), 2.56 (t, J = 7.4 Hz, 2, SCH 2), 4.05-4.07 (m, 2, H2',4'), 4.19-4.26 (m, 2, H5',5"),
5.20 (t, J = 7.3 Hz, 1, H3'), 6.07 (br s, 2, NH2), 6.34 (d, J = 3.5 Hz, 1, H1'), 8.03 (s, 1,
H2), 8.29 (s, 1, H8); MS (APCI) In/, 600 (100, MH+).
2'-Deoxy-2'-propyldithioadenosine (22)
Treatment of 21 (60 mg, 0.1 mmol) by procedure F gave 22 (12.4 ing, 35%): UV
max 260 nm (F 14 200), min 229 nm (e 2 600); 'H NMR (MeOH-d,) 6 0.74 (t, J = 7.3 Hz,
45
3, CH), 1.36 (sextet, J = 7.05 Hz, 2, CH,), 2,18-2.24 (m, 2, CHS), 3.80-3.89 (m, 2,
H5',5"), 4.19-4.25 (m, 1, H4'), 4.27-4.31 (m, 1, H2'), 4.55 (d, J= 7.0 Hz, 1, H3), 6.20 (d,
J= 9.2 Hz 1, H1), 8.22 (s 1, 1 H2), 8.35 (s, 1, H8); MS (APCI) i/z 358 (100, MH).
3.3. SYNTHESIS OF FLUORO-CONTAINING COMPOUNDS
Tritylation of Adenosine
A mixture of dried adenosine (1, 5 g, 18.7 mmol), DMAP (1.92 g, 15.7 mmol),
and TrCI (17.5 g, 62.6 miol) in 150 mL of pyridine was heated at 80 "C. An additional
amount of TrCI (5 g) was added after 18 h. The reaction was quenched with EtOH (50
mL) after 40 h. Solvent was evaporated, and the residue was partitioned
(NaHCO3/H20//EtOAc). The organic layer was washed (NaCl/H 20), dried (MgSO 4),
filtered, and evaporated. This crude material was chromatographed on a silica gel
column. Gradient elution (15% EtOAc/Hexanes - 30% EtOAc/Hexanes) and
evaporation of the appropriate fractions gave compounds 03, O5, N'-Tritrityladenosine
(23) and 0, 05, N'-Tritrityladenosine (24).
Compound 23 (3.6 g, 19%), mp 152-155 "C, was eluted first: 1H NMR 6 2.59 (dd,
J4'5 = 6.1 Hz, J5 5" = 10.9 Hz, 1, H5"), 3.25 (dd, J4'5 = 1.8 Hz, 1, H5'), 3.33-3.39 (m, 1,
H4'), 4.25-4.27 (m, 1, H3'), 4.62-4.71 (m, 1, H2'), 6.15 (d, J,2 = 6.2 Hz, 1, Hi'), 7.02-
7.41 (m, 45, 3 x Tr), 8.05 (s, 1, H2), 8.09 (s, 1, H8) and other data as reported.50
Compound 24 (4.1 g, 22%), mp 152-154 C, was eluted next: 'H NMR 62.87-
2.88 (m, 1, H4'), 3.03 (dd, J4 5" = 4.4, Jr5.= 10.4 Hz, 1, H5"), 3.30 (dd, J4'- = 3.4 Hz, 1,
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H5'), 3.99-4.01 (m, 1, H3'), 5.15-5.18 (m, 1, H2'), 6.37 (d, = 7.4 Hz, 1, H1'), 7.08-
7.44 (m, 45, 3 x Tr), 7.90 (s, 1, H2), 7.99 (s, 1, H8) and other data as reported.50
2'-O-Trifly-3',5'-di-0-trityl--trityladeosine (25). Procedure G
To a mixture of 23 (1.4 g, 1.41 mol), DMAP (169 mg, 1.41 mmol), and Et3N
(392 pL, 2.8 miol) in CH 2C2 (12 mL) was added dropwise a solution of CF 3SO 2Cl (300
tL). The reaction mixture was stirred at room temperature for 30 min. The mixture was
concentrated in vacuio, and the residue was partitioned (H2O//CHC13). The organic layer
was washed (NaCl/H20), dried (MgSO 4), filtered, and evaporated. The residue was
chromatographed on a column of silica gel with CHCl 3 to give 2550 (1.4 g, 90%) as a
foam: 'H NMR 2 .92 (dd, J4- = 3.7 Hz, J5.5~= 11.1 Hz, 1, H5"), 3.33 (d, 1, H5'), 3.68-
3.72 (m, 1, H4'), 4.64-4.66 (m, 1, H3'), 5.92 ("t", J2'-1.3= 5.5 Hz, 1, H2'), 6.73 (d, J1_2' =
6.4 Hz, 1, H1'), 7.28-7.48 (m, 45, 3 x Tr), 8.05 (s, 1, H2), 8.1 (s, 1, H8).
'-O-Triflyl-2',5'-di-O-trityl-N -trityladenosine (26)
Treatment of 24 (1.5 g, 1.51 miol) by procedure G gave 2653 (1.5 g, 88%): 'H
NMR b 3.17 (dd, 14 - 5" = 4.9 Hz, J5'-5= 10.2 Hz, 1, H5"), 3.35 (dd, J4{5 = 7.6 Hz, 1, H5'),
4.32-4.35 (n, 2, H3',4), 5.97 (dd, J29.3 = 4.2 Hz, Jr' = 7.9 Hz, 1, H2'), 6.14 (d, J'-2' = 7.9
Hz, 1, H1'), 7.22-7.37 (m, 45, 3 x Tr), 7.56 (s, 1, H2), 7.83 (s, 1, H8).
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-(3,5-Di- -trityl-- -- arabinouraosyl)-"-tritylaenine (29). Procedure H
A mixture of 25 (1 g, 0.89 mmol) and AcONa (1 g, dried at 60 'C under vacuum)
in 20 mL of DMF was stirred for 3 days at room temperature. Solvent was evaporated
and the residue was partitioned between H20 and EtOAc. Organic layer was washed with
H2O twice, dried (MgSO4), filtered, and evaporated. Residue was suspended in
MeOH/NH, (50 mL), stirred 24 h, and concentrated in vacuo. The resulting solid was
column chromatographed on silica gel with CHC 3 to give 2950 (644 mg, 73%): H NMR
S2.96 (dd, J4'5" = 3.5 Hz, J5 5" = 10.5 Hz, 1, H5"), 3.42 (dd, J4 -5, = .9 Hz, 1, H5'), 3.61-
3.66 (m, 1, H2'), 3.94-3.98 (m, 1, H4'), 4.07 (s, 1, H3'), 6.31 (d, JF-2' = 2.3 Hz, 1, H1'),
7.01 (s, 1, NH), 7.19-7.39 (i, 45, 3 x Tr), 8.05 (s, 1, H2), 8.35 (s, 1, H8).
9-(2,5-Di-O-trityl-f-D-xylofuranosyl)-N -trityladenine (30)
Treatment of 26 (1 g, 0.89 mmol) by procedure H gave 33,4 (660 mg, 75%): 'H
NMR 6 3.47 (dd, J4'5" = 3.6 Hz, J5 _5" = 10.7 Hz, 1, H5"), 3.57 (dd, J4'5' = 7.5 Hz, 1, H5'),
3.95-4.02 (m, 1, H3), 4.29-4.36 (m, 1, H4'), 4.58 (s, 1, H2), 5.47 (s, 1, H1'), 6.96-7.43
(in, 47, H2, NH, 3 x Tr), 8.01 (s, 1, H8).
2'-Deoxy-2'-fluoro-3',5'-di-0-trityl-M-trityladenosine (31). Procedure I
To an ice-cold solution of 29 (550i mg, 0.6 mmol) and pyridine (0.6 mL, 6 mmol)
in CH2Cl 2 (7.5 mL) were added 0.38 mL of DAST (443.3 mg, 3 miol). Ice was removed
after 5 min. Mixture of reaction was stirred overnight at room temperature, then diluted
with of CH-CL (5.5 mL) and quenched by addition of 5% NaHCO3 (4 mL). The organic
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layer was separated, washed with H20, dried (MgSO 4 ), filtered, and concentrated in
vacuo. The residue was chromatographed on a silica gel column with CHCI 3 to afford
compound 3150 (260 mg, 47%): 'H NMR 2 .89 (dd, J4-5 = 5.2 Hz, J 55 = 10.9 Hz, 1,
H5"), 3.30 (d, 1, H5'), 3.92-3.95 (m, 1, H4'), 4.46 ("dt", J3'2 /4'= 5.0 Hz, J3s.F= 13.1 Hz, 1,
H3'), 4.85 (dt, J2-1,r3 = 4.0 Hz, J2'-F= 51.6 Hz, 1, H2'), 6.27 (dd, J-2= = 3.5 Hz, JI'.F= 14.7
Hz, 1, HF), 6.98 (s, 1, NH), 7.12-7.39 (m, 45, 3 x Tr), 7.80 (s, 1, H2), 7.96 (s, 1, H8); ' 9F
NMR -201.8 (dt, Ji/3'-F= 15 Hz, J2'F= 50 Hz).
3'-Deoxy-3'-fluoro-2',5'-di-O-trityl-N'-trityladenosine (32)
Treatment of 30 (650 mg, 0.65 mmol) by procedure I gave compound 32 '54 (550
mg, 84%): 'H NMR 6 3.05 (dd, J4'5 = 3.5 Hz, J-'5 = 10.4 Hz, 1, H5"), 3.33 (dd, J'-5'=
4.6 Hz, J>'5 = 10.5 Hz, 1, H5'), 3.60 (dd, J,' 2 '= 3.8 Hz, J3 -F = 53.1 Hz, 1, H3'), 4.24 (dt,
14.5/5 = 3.7 Hz, J4'-F = 35.0 Hz, 1, H4'), 4.85 (ddd, J21' = 7.6 Hz, JUY = 3.8 Hz, J2 -F 21.6
Hz, 1, H2'), 6.27 (d, Jr-2. = 7.7 Hz, 1, H1'), 7.08-7.44 (m, 46, NH, 3 x Tr), 7.81 (s, 1, H2),
7.89 (s, 1, H8); '9F NMR -192.55 (dt, J2'/4-F= 27 Hz, J3-F= 52 Hz).
9-(2-Deoxy-2-fluoro-3,5-di-0-trityl- -D-arabinofuranosyl)-N 6 -trityladenine (33)
Treatment of 23 (1 g, 1.01 mmol) by procedure I gave compound 3350 (309.7 mg,
31%): 'H NMR 6 3.28 (dd, J4 -5 = 2.7 Hz, J5'5, = 10.0 Hz, 1, H5"), 3.34 (dd, J4 _5' =7.6
Hz, J5 s5 =9.9 Hz, 1, H5'), 3.73 (dd, J? - =2.2 Hz, J2 F= 50.1 Hz, 1, H2'), 4.31 (dd, J,'4'=
2.5 Hz, J3'F = 16.1 Hz, 1, H3'), 4.60 (dt, J4'-37 = 2.7 Hz, ] 4 .5'= 7.1 Hz, 1, H4'), 6.45 (dd,
Jr-2 = 2.2 Hz, J'-F = 24.7 Hz, 1, H1'), 7.03 (s, 1, NH), 7.24-7.46 (m, 45, 3 x Tr), 7.89 (s,
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1, H2), 8.09 (s, 1, H8); '9 F NMR 6-195.74 (ddd, JI F = 16 Hz, J3-F = 23 Hz, J2'-F = 50
Hz).
9-(3-Deoxy-3-fluoro-2,5-di-O-trity- ®-D-xylofuranosyl)-N6 -trityladenine (34)
Treatment of 24 (1 g, 1.01 mmol) by procedure I gave compound 34 (505.2 mg,
51%): 'H NMR 6 3.33 (dd, JT-5" = 6.3 Hz, J5'-5 = 9.7 Hz, 1, H5"), 3.53 (dd, J4 -5 = 6.7 Hz,
J '-5 = 9.0 Hz, 1, H5'), 3.76 (dd, J3'4 = 1.7 Hz, J3 -F = 50.2 Hz, 1, H3'), 4.27 (dtd, J4 - =
1.7 Hz, J4-575"= 6.3 Hz, J4'F = 31.2 Hz, 1, H4'), 4.44 (dd, J2,, = 1.1 Hz, J2'-F = 14.1 Hz, 1,
H2'), 6.53 (d, Jp- 2' = 1.1 Hz, 1, HI'), 6.99 (s, 1, NH), 7.21-7.45 (m, 45, 3 x Tr), 7.69 (s, 1,
H2), 8.18 (s, 1, H8); '9F NMR 6-200.02 (ddd, J2 '-F= 14 Hz, J4 -F= 31 Hz, J3.-F= 50 Hz).
2'-Deoxy-2'-fluoroadenosine (35). Procedure J
Compound 31 (250 mg, 0.25 mmol) was dissolved in a mixture (7 mL) of
CFCOOH-CHCl, (1:9, v/v) and kept at room temperature for 24 h, then partitioned with
H20. The aqueous layer was first concentrated, then applied to a column of Dowex 1x2-
200 (OH-) ion-exchange resin and eluted with 30% MeOHH20. Evaporation of the
appropriated fraction gave compound 3550 (45.2 mg, 49%): 'H NMR (MeOH-d4 ) 6 3.79
(dd, J4 -5 = 3.0 Hz, J5'5" = 12.6 Hz, 1, H5"), 3.96 (dd, J4.5" = 2.0 Hz, J5'_5 = 12.6 Hz, 1,
H5'), 4.45-4.82 (m, 1, H4'), 4.64 (ddd, J3-2 = 4.7 Hz, J3..4 = 5.7 Hz, J3-F = 15.9 Hz, 1,
H3'), 5.45 (ddd, J2,, = 3.5 Hz, J2 3= 4.3 Hz, J2'-F = 52.7 Hz, 1, H2'), 6.32 (dd, J-2= = 3.3
Hz, JI'-F = 15.7 Hz, 1, Hi'), 8.22 (s, 1, H2), 8.41 (s, 1, H8); '9F NMR 6-208.41 (dt, J1/3,-F
= 15 Hz, J-2'r = 53 Hz).
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3'-Deoxy-Y-fluoroadenosine (36)
Treatment of 32 (540 mg, 0.54 mmol) by procedure J gave compound 3655 (145.9
mg, 86%): 'H NMR (MeOH-d4) 6 3.81 (dd, J4-5" = 2.1 Hz, J5'5"= 12.7 Hz, 1, H5") 3.88
(dd, J4-5. = 2.1 Hz, J5 - = 12.7 Hz, 1, H5'), 4.46 (dt, J4'5/5" = 2.1 Hz, J4'®r = 27.7 Hz, 1,
H4'), 4.99 (ddd, J,,, = 8.0 Hz, J2.3= 4.3 Hz, JF =25.2 Hz, 1, 2'), 5.13 (dd, J3'-2 = 4.2
Hz, J3-F = 54.5 Hz, 1, H3'), 6.02 (d, Jli. = 8.0 Hz, 1, H1'), 8.2 (s, 1, H2), 8.3 (s, 1, H8);
'
9F NMR 6 -200.39 (dt, J,/4'-F= 27 Hz, J3'-F= 54 Hz).
9-(2-Deoxy-2-fiuoro-$-D-arabinofuranosyl)adenine (37)
Treatment of 33 (280 mg, 0.28 mmol) by procedure J gave compound 37 (50.3
mg, 66%): 'H NMR (MeOH-d4) 3.81 (dd, J4'5" = 7.1 Hz, J'-" = 12.2 Hz, 1, H5"), 3.83
(dd, J4.- = 4.0 Hz, J5 5" = 12.2 Hz, 1, H5'), 4.02 ("q", J 375r'l = 4.7 Hz, 1, H4'), 4.54 (ddd,
Jry- = 3.1 Hz, J3 4'= 4.6 Hz, J-F = 18.1 Hz, 1, H3'), 5.15 (ddd, J 2,I = 4.0 Hz, J2'- = 3.1
Hz, J2' F = 52.2 Hz, 1, H2'), 6.49 (dd, J, 2 = 4.1 Hz, J1-F = 16.0 Hz, 1, H1'), 8.23 (s, 1,
H2), 8.36 (s, 1, H8); F NMR 6-200.01 (dt, Ji/3'-F = 18 Hz, J'-F= 53 Hz) and other data
as reported. 0 '5
9-(3- Deoxy-3-fluoro- -D-xylofuranosyl)adenine (38)
Treatment of 34 (480 mg, 0.48 mmol) by procedure J gave compound 38 5 (50.1
mg, 39%): 'H NMR (MeOH-d4) 63.96 (dd, J4 .5~ = 6.1 Hz, J ,- = 11.7 Hz, 1, H5"), 3.98
(dd, J'_' = 5.6 Hz, Js- = 11.7 Hz, 1, H'), 4.49 (dtd, J4'- = 3.2 Hz, J4s/5" = 5.8 Hz, J4'-F
27.9 Hz, 1, H4'), 4.73 (dt, Jer 3 = 1.7 Hz, J2 '-F = 13.7 Hz, 1, H2'), 5.12 (ddd, J;-, = 1.8
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Hz, J'-'= 2 .8 Hz , J3p.F = 51.7 Hz, 1, H3'), 6.10 (d, JF-2 = 1.7 Hz, 1, H1'), 8.18 (s, 1, H2),
8.23 (s, 1, H8); "F NMR -204.12 (ddd, J2'-F= 14 Hz, J4'F= 28 Hz, J tF= 52 Hz).
5'-O-(tert-Butyldinethylsilyl)-2'-deoxy-2'-fluoroadenosine (39). Procedure K
TBDMSCl (63 mg, 0.44 mrnol) and imidazole (43 mg, 0.66 mmol) were added to
35 (59 g, 0.22 mmol) in dried DMF (3.0 ml) and the solution was stirred overnight at
ambient temperature. H20 (1.0 ml) was added, volatiles were evaporated, and the residue
was partitioned (EtOAc//N CI/H20). The organic layer was washed (brine), dried
(Na2S04), evaporated and chromatographed (5 -+ 10% MeOH/CHCl3) to give 39 (39 mg,
46%): H NMR 6 0.14 (s, 6, (CH 3)2Si), 0.93 (s, 9, (CH 3)3CSi), 3.93 (dd, J4,5" = 2.5 Hz,
J5'-= 11.7 Hz, 1, H5"), 4.09 (dd, 14-5 = 2.4 Hz, Js'-= 11.7 Hz, 1, H5'), 4.19-4.25 (m, 1,
H4'), 4.72 (ddd, J3 2 = 4.4 Hz, Jh34 = 6.5 Hz, J3.F = 17.5 Hz, 1, H3'), 5.45 (ddd, J2,1 = 2.2
Hz, JT-Y = 4.2 Hz, J2'-F= 52.9 Hz, 1, H2'), 6.02 (dd, Jr-2. = 2.2 Hz, JI VF = 15 Hz, 1, H1'),
8.23 (s, 1, H2), 8.38 (s, 1, H8); 'F NMR 6-204.33 (dt, J1/3-F= 16 Hz, J25F= 53 Hz); MS
(CI) //,384 (100, MH}).
5'-O-(tert-Butyldimethylsilyl)-3'-deoxy-3'-fluoroadenosine (40)
Treatment of 36 (80 mg, 0.3 mmol) by procedure K gave compound 40 (56.5 mg,
50%): 'H NMR -0.02 (s, 3, CH3Si), 0.04 (s, 3, CH 3Si), 0.79 (s, 9, (CH3)3CSi), 3.85 (m,
2, H5',5"), 4.58 (dt, J4-5.15 = 2.8 Hz, J4F = 26.4 Hz, 1, H4'), 4.74 (ddd, J2,-I= 7.0, JJe =
4.5 Hz, J2-F = 24.7 Hz, 1, H2'), 5.19 (dd, J3,2.= 4.4 Hz, JF = 54.5 Hz, 1, H3'), 6.02 (d, Jr-
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2' = 7.2 Hz, 1, H1'), 8.08 (s, 1, H2), 8.33 (s, 1, H8); "9F NMR 6-199.45 (dt, J2'4-F= 26
Hz, J3,-F= 54 Hz); MS (CI) in! 384 (100, MH).
9-[5-O-(tert-Butyldimethylsilyl)-2-deoxy-2-fluoro-$-D-arabinofuranosyl]adenine (41)
Treatment of 37 (40 mg, 0.15 mmol) by procedure K gave compound 4156 (36.5
mg, 64%): 'H NMR 0.14 (s, 6, (CH 3)2Si), 0.95 (s, 9, (CH 3)3CSi), 3.88 (dd, J4 _5 = 6.4
Hz, J-5" = 10.8 Hz, 1, H5"), 3.95 (dd, Jt 5, = 3.5 Hz, J5 '-5 = 10.8 Hz, 1, H5'), 4.02 ("q", J4'
3755"= 4.4 Hz, 1, H4'), 4.69 (dt, JY-2 = 3.2 Hz, JY-F = 17.6 Hz, 1, H3'), 5.15 (dt, J2'173 =
3.6 Hz, J-TF = 51.6 Hz, 1, H2'), 6.5 (dd, J -2, = 3.7 Hz, Jl 'F= 18.0 Hz, 1, H1'), 8.13 (s, 1,
H2), 8.37 (s, 1, H8); "F NMR 6 -198.02 (dt, J13,_F = 17 Hz, J2-F= 51 Hz).
9-[5-0-(tert-Buty(dimethylsilyl)-3-deoxy-3-fluoro-$-D-xylofuranosyl]adenine (42)
Treatment of 38 (45 mg, 0.17 mmol) by procedure K gave compound 42 (44.5
mg, 69%): 'H NMR 60.11 (s, 6, (CH3) 2Si), 0.91 (s, 9, (CH 3)3CSi), 4.03 (dd, J4 .5' = 6.1
Hz, J5-5 = 10.2 Hz, 1, H5"), 4.08 (dd, 145- = 6.4 Hz, J.5" = 10.5 Hz, 1, H5'), 4.56 (dtd, J-
Y = 3.3 Hz, J-5/5= 5.9 Hz, J4'-F = 26.9 Hz, 1, H4'), 4.66 (dt, ?e-13 = 1.7 Hz, J2'-F = 15.4
Hz, 1, H2'), 5.16 (ddd, J,' = 2.0 Hz, J3.4= 2.9 J3'-F = 51.2 Hz, 1, H3'), 6.01 (d, Jr-2, = 1.5
Hz, 1, H'), 7.99 (s, 1, H2), 8.31 (s, 1, H8); '9F NMR 6-203.72 (ddd, J2'-F= 16 Hz, J4 .F=
26 Hz, J3'-F= 50 Hz); MS (CI) il!z 384 (100, MH+).
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S'-O-(tert-Butyldimethylsilyl)-2'-deoxy-2'-fluoro-3 '- -
(ph enoxythiocarbonyl)adenosine (43). Procedure L
PTCCI (21.5 pL, 27 mg, 0.15 mmol) was added dropwise to a stirred solution of
39 (39 mg, 0.1 mmol) and DMAP (55 mg, 0.45 mmol) in acetonitrile (3.0 mL). Stirring
was continued for 5 h, and volatiles were evaporated. The residue was partitioned
(EtOAc/HO), and the organic layer was washed (0.1 M HCI/H 20, NaHCO3/H90,brine),
dried (Na2SO 4), evaporated, and column chromatographed (30% hexane/EtOAc -+
EtOAc) to give 43 (35 mg, 66%): 'H NMR b 0.15 (s, 6, (CH 3)2Si), 0.95 (s, 9, (CH 3)3CSi),
3.98 (dd, J45" = 2.0 Hz, J55= 1.8 Hz, 1, H5"), 4.11 (dd, J4'. = 1.7 Hz, J55= 11.7 Hz,
1, H5'), 4.61 (m, 1, H4'), 5.77 ("dt", J2,-/ = 3.9 Hz, J>4F= 51.7 Hz, 1, H2'), 6.04 ("dt", Jy_
2'4 = 5.6 Hz, J 3 -F= 13.1 Hz, 1, H3'), 6.47 (dd, Jl-2' = 3.2 Hz, J F = 15 Hz, 1, HI'), 7.15 (d,
J = 8.5 Hz, 2, Harom), 7.35 (t, J = 7.3 Hz, 1, Haron), 7.47 (t, J = 7.8 Hz, 2, Hr(om), 8.2 (s, 1,
H2), 8.39 (s, 1, H8); 'F NMR 6 -205.26 (dt, J1/3-F = 14 Hz, J2'-F = 51 Hz); MS (CI) n/7
520 (100, MH+).
5'-O-(tert-Butyldimethylsilyl)-3 '-deoxy-3'-fluoro-2'-O-
(phenoxythiocarbonyl)adenosine (44)
Treatment of 40 (24 mg, 0.062 mmol) by procedure L gave compound 4456 (24
mg, 74%): 'H NMR 6 0.16 (s, 6, (CH 3)25i), 0.96 (s, 9, (CH 3)3CSi), 3.93 (dd, J4'-5 = 2.5
Hz, J5 = 11.5 Hz, 1, H5"), 4.01 (dd, J4'_ = 1.6 Hz, J5- = 11.4 Hz, 1, H5'), 4.59 (dt, J4,.
5'/5= 1.7 Hz, J4 -F = 25.8 Hz, 1, H4'), 5.61 (dd, J3-2'= 4.3 Hz, J3'-F = 54.1 Hz, 1, H3'), 6.28
(ddd, J2t1 = 7.6 Hz, J23= 4.3 Hz, J2-F = 20.8 Hz, 1, H2'), 6.6 (d, J-2' = 7.2 Hz, 1, HI'),
7.07 (d, J= 7.6 Hz, 2, Harom), 7.3 (t, J = 7.3 Hz, 1, Harom), 7.41 (t, J = 7.6 Hz, 2, Harom),
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8.2 (s, 1, H2), 8.42 (s, 1, H8); "F NMR -199.24 (ddd, J'-F = 21 Hz, J4-F= 26, 1 3T = 54
Hz); MS (CI) mz 520 (100, MH+).
9-[5-O-(tert-Butyldirnethylsilyl)-2-deoxy-2-fluoro-3-O-(phenoxythiocarbony)-$-D-
arabinofuranosyl]adenine (45)
Treatment of 41 (36 mg, 0.094 mmol) by procedure L gave compound 45 (19 mg,
38%): 'H NMR 6 0.15 (s, 6, (CH 3)2Si), 0.96 (s, 9, (CH,);CSi), 3.95 (dd, J4'5" = 4.8 Hz,
J5-5"= 10.7 Hz, 1, H5"), 4.02 (dd, J4-5' = 4.7 Hz, Js5"= 11.0 Hz, 1, H5'), 4.39-4.44 (m, 1,
H4'), 5.57 (dd, J2i, = 2.8 Hz, J2'-F= 49.6 Hz, 1, H2'), 6.01 (dd, J3'.4'= 2.6 Hz, J3.F = 15.6
Hz, 1, H3'), 6.59 (dd, J,<2. = 2.6 Hz, Jl'-F = 22.0 Hz, 1, HI'), 7.16 (d, J = 7.6 Hz, 2, Harom),
7.36 (t, J = 7.3 Hz, 1, Harom), 7.47 (t, J = 7.6 Hz, 2, Haron), 8.16 (s, 1, H2), 8.40 (s, 1, H8);
"F NMR 6-199.19 (dt, J1'3'-F= 18 Hz, J2'-F= 51 Hz); MS (CI) m/z 520 (100, MH').
9-[5- -(tert-Butyldimethylsilyl)-3-deoxy-3-fluoro-2-O-(phenoxytiocarbonyl)- -D-
xylofuranosyl]adenine (46)
Treatment of 42 (44 mg, 0.12 mmol) by procedure L gave compound 46 (15 mg,
25%): 'H NMR 6 0.14 (s, 6, (CH 3)2Si), 0.95 (s, 9, (CH 3)3CSi), 3.99-4.09 (m, 2, H5',5"),
4.49 (dtd, J4'-3'= 3.0 Hz, J4.515"= 7.5 Hz, J4.F = 28.5 Hz, 1, H4'), 5.39 (dd, J3'4 = 2.6 Hz,
J3sF= 49.8 Hz, 1, H3'), 6.09 (d, J2F= 13.3 Hz, 1, H2'), 6.5 (s, 1, H1'), 7.15 (d, J= 7.5 Hz,
2, Har1m), 7.36 (t, J = 7.8 Hz, 1, Harom), 7.46 (t, J = 7.8 Hz, 2, Harom), 8.09 (s, 1, H2), 8.4
(s, 1, H8); F NMR 6 -204.49 (ddd, J2-F = 13 Hz, J4'-F = 28 Hz, JTF = 50 Hz); MS (CI)
/lz 520 (100, MH+).
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pentafuranosyl)adenine (47). Procedure M
A solution of 43 (17 mg, 0.032 mmol), AIBN (1.2 mg, 0.007 mmol) and BuSnD
(17.4 L, 18 mg, 0.064 mmol) in toluene (1.0 mL) was deoxygenated (Ar) for 30 min and
then was gently heated for 3 h at 85 "C. Volatiles were evaporated and the residue was
column chromatographed (EtOAc) to afford 47 (3R/S, ~64:36; 8. mg, 67%): 'H NMR 6
0.13 (s, 6, (CH3)2Si), 0.96 (s, 9, (CH 3);CSi), 2.23 (dd, Jb 4 ' = .1 Hz, J3'b.F = 19.3 Hz,
0.36, H3'b), 2.49 (ddd, J3a-2' = 4.0 Hz, Ja-4 = 10.7 Hz, J3'a-F = 42.3 Hz, 0.64, H3'a), 3.8
(dd, J45" = 2.7 Hz, J5'5" = 11.7 Hz, 1, H5"), 4.15 (dd, J4'-5 = 2.5 Hz, J5a- = 11.7 Hz, 1,
H5'), 4.6 (dt, J4-5 5 = 2.6 Hz, Je-3a. = 10.6 Hz, 1, H4'), 5.42 (dd, J2,3a,= 3.7 Hz, J2'-F= 51.5
Hz, 1, H2'), 6.33 (d, J1.F = 16.5 Hz, 1, HI'), 8.29 (s, 1, H2), 8.34 (s, 1, H8); 'F NMR S -
181.04 (ddd, J,'-F= 16.5 Hz, 3 'a-F 42 Hz, J2'-F= 51.5 Hz) and other data as reported.
9-[5-0-(tert-Butyldimethylsilyl)-2(R/S)-deuterio-3- uro-2,3-dideoxy-p-D-erythro-
pentafuranosyl]adenine (48)
Treatment of 44 (17.5 mg, 0.034 mmol) by procedure M gave compound 48
( R/S, -16:84; 4 mg, 33%): 'H NMR 0.13 (s, 6, (CH 3)2Si), 0.93 (s, 9, (CH 3)3CSi), 2.73
(ddd, J2b-,.= 8.7 Hz, J2',b3 = 4.8 Hz, J2'b-F = 39.1 Hz, 0.84, H2'b), 2.82 (dd, J2,a-3 = 4.2 Hz,
J2'a-F = 18.8 Hz, 0.16, H2'a), 3.88 (dd, J4'-5" = 3.0 Hz, J5,5 = 112 Hz, 1, H5'), 3.93 (dd, J4 -
5 = 3.7 Hz, J5' 5 = 11.4 Hz, 1, H5'), 4.44 (dt, J- 57y= 3.3 Hz, J4'-F = 26.4 Hz, 1, H4'), 5.36
(dd, J-32t= 4.6 Hz, J3'-F= 53.5 Hz, 1, H3'), 6.55 (d, Jl -2'b = 8.9 Hz, 1, H1'), 8.18 (s, 1, H2),
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8.37 (s, 1, H8); "'F NMR --176.95 (ddd, J4'-F = 26.6 Hz, J2'b-F 37.7 Hz, J3-F = 52.7 Hz)
and other data as reported.
9-[5-0-(tert-Butyldimethylsilyl)-3(R/S)-deuterio-2-fluoro-2,3-dideoxy-$-D-threo-
pentafuranosyl]adenine (49)
Treatment of 45 (10 mn, 0.02 mmol) by procedure M gave compound 49 (3R/S,
-93:7; 6.5 mg, 90%) with data as reported56 except: 'H NMR 0.13 (s, 6, (CH 3)2Si), 0.95
(s, 9, (CH 3)CSi), 3.85-3.87 (m, 2, H5',5"), 4.30 ("q", J4-37575" = 5.09 Hz, 1, H4'), 2.46
(dd, J 4 = 3.4 Hz, J3'-F= 26.8 Hz, 0.93, H3'), 5.30 (dt, J2'r/3 = 2.56 Hz, J2,F= 53.6 Hz, 1,
H2'), 6.34 (dd, JF-2' = 3.2 Hz, JI'F = 18.1 Hz, 1, H1'), 8.18 (s, 1, H2), 8.37 (s, 1, H8); 9F
NMR 6-188.04 (dt, J,/3'F= 23 Hz, J2'-F= 3 Hz).
9-[5- -(tert-Btylethylsilyl)-2(R/S)-deuterio-3-fuoro-2,3-dideoxy®---threo-
pentafuranosyl]adenine (50)
Treatment of 46 (8.6 mg, 0.017 mmol) by procedure M gave compound 50 (T'RS,
~6:94; 2.5 mg, 54%): 'H NMR 6 0.11 (s, 6, (CH 3)2Si), 0.93 (s, 9, (CH 3)3CSi), 2.72 (d, J2
F- 15.4 Hz, 0.93, H2'), 3.99 (dd, J4.5 = 5.9 Hz, J5'-= 10.2 Hz, 1, H5"), 4.04 (dd, J4-5 =
7.1 Hz, J5-5"= 10.1 Hz, 1, H5'), 4.20 (dddd, J4-3.= 2.5 Hz, J4 -5= 6.0 Hz, J'-5 = 7.2 Hz, J4,-
F = 28.6 Hz, 1, H4'), 5.36 (dd, J3'4 = 2.0 Hz, J3'-F = 53.4 Hz, 1, H3'), 6.56 (s, 1, H1'), 8.13
(s, 1, H2), 8.34 (s, 1, H8); '9F NMR 6-193.82 (ddd, J4 -F = 27 Hz, J2'-F = 22 Hz, J3'-F = 54
Hz).
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9-[3(R/S)-deuterio-2-f uoro-2,3-dideoxy-f-D-erythro-pentafuranosyl]adenine (51)
Procedure N
NH4F (100 mg, 2.7 mmol) was added to 47 (15 mg, 0.04 mmol) in MeOH (2 rnL),
and stirring was continued overnight at reflux. Volatiles were evaporated and the residue
was chronatographed (5 10% MeOH/CHCl3) to give compound 51 (3'R/S, ~62:38; 5.5
mg, 55%): 'H NMR (MeOH-d4) 6 2.3 (dd, J;b-4'= 5.4 Hz, J3'b-F = 19.5 Hz, 0.36, H3'b),
2.53 (ddd, Ja7-2'= 4.3 Hz, J3 a-r = 9.7 Hz, J3'a-F = 38.2 Hz, 0.64, H3'a), 3.72 (dd, J4'5" = 3.2
Hz, J>'_- = 12.5 Hz, 1, H5"), 4.01 (dd, J4'_' = 2.2 Hz, Js'-5 = 12.4 Hz, 1, H5'), 4.53-4.57
(m, 1, H4'), 5.52 (dd, J2 'a = 4.2 Hz, J2'-F = 52.0 Hz, 1, H2'),_6.3 (d, J 'F = 16.8 Hz, 1,
H1'), 8.22 (s, 1, H2), 8.45 (s, 1, H8); bF NMR (MeOH-d4) 6 -182.62 (ddd, JF-F = 16 Hz,
J3'a-F = 38 Hz, J2-F = 52 Hz); MS (CI) n/z 255 (100, MH); and other properties as
reported for unlabeled analog.3 3
9- [2(R/S)-deuterio-3-fluoro-2,3-dideoxy- -D-erythro-pentafuranosyl]adenine (52)
Treatment of 48 (5 mg, 0.014 mmol) by procedure N gave compound 52 (2R/S,
~13.5:86.5; 2.8 mg, 81 %): 'H NMR (MeOH-d 4) 6 2.12 (dd, J2b-3= 5.4 Hz, J2'b-F 20.6
Hz, 0.14, H2'b), 2.4 (ddd, J2'a-r = 4.3 Hz, J2'a-r = 9.3 Hz, J2'a-F = 40.8 Hz, 0.86, H2'a), 3.25
(dd, J4'5" = 2.7 Hz, J5'5" = 12.5 Hz, 1, H5"), 3.3 (dd, J4'5' = 2.7 Hz, J5'5" = 12.4 Hz, 1,
H5'), 3.84 (dt, J4'-55= 2.7 Hz, J4 '-F = 27.3 Hz, 1, H4'), 4.86 (dd, J3'2' = 4.6 Hz, J3'F= 53.6
Hz, 1, H3'), 5.89 (d, J1-2'a = 9.42 Hz, 1, H1'), 7.73 (s, 1, H2), 7.62 (s, 1, H8); '9F NMR
(MeOH-d4) -173.44 (ddd, J4 F = .28 Hz, J2'a-F = 41 Hz, J;3F = 5 Iz); MS (CI) m/z 255
(100, MH); and other properties as reported for unlabeled analog.
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-[3(R/S)-deuterio-2-fluoro-2,3-dideoxy- -D-threo-pentaf ranosyl]adenine (53)
Treatment of 49 (12.5 mg, 0.035 mol) by procedure N gave compound 53
(3'R/S, ~92.5:7.5; 4. mg, 54%): 'H NMR (MeOH-d 4) 6 1.8 ("dt", '-24= 4.2 Hz, J3'b-F=
27.2 Hz, 0.93, H3'b), 2.05 ("dt", J3,-2/4 = 6.8 Hz, J3'a-F = 31.0 Hz, 0.07, H3'a), 3.2 (dd, J4,
5" = 6.5 Hz, Js5" = 12.0 Hz, 1, H5"), 3.27 (dd, J4-s' = 3.7 Hz, J 55 = 12.0 Hz, 1, H5'), 3.77
("q", J4'3'b/5/5 = 5.2 Hz, 1, H4'), 4.79 (dt, -1/3'b = 2.7 Hz, J2 '-F = 54.1 Hz, 1, H2'), 5.76
(dd, JI- = 3.5 Hz, J'-F = 16.8 Hz, 1, H1'), 7.66 (s, 1, H2), 7.81 (s, 1, H8); '9F NMR
(MeOH-d4) 6-182.62 (ddd, JIeF = 17 Hz, J3'b-F 27 Hz, J '-F = 54 Hz); MS (CI) n/z 255
(100, MH'); and other properties as reported for unlabeled analog,33'56
9-[2(R/S)-deuteri-3-fluoro-2,3-dideoxy--D-threO-pentafuranosyl]adenine (54)
Treatment of 50 (4 mg, 0.011 mmol) by procedure N gave compound 54 (2R/S,
~8:92; 2.7 mg, 98%): 'H NMR (MeOH-d 4) 6 2.75 (dd, J2'b-1 = 1.4 Hz, J2b-F = 21.3 Hz,
0.9, H2'b), 2.96 (dd, J2a- = 7.1 Hz, J2'a-F = 45.9 Hz, 0.1, H2'a), 3.89 (dd, J45~ = 6.6 Hz,
J5-5~= 11.6 Hz, 1, H5"), 3.96 (dd, J4.5 = 5.9 Hz, J55. = 11.6 Hz, 1, H5'), 4.26 (dtd, J-3 =
2.7 Hz, J4-51-= 6.4 Hz, J4.-F = 29.2 Hz, 1, H4'), 5.42 (dd, J3' = 2.6 Hz, J3.-F = 54.1 Hz, 1,
H3'), 6.59 (d, Ji-t-2. = 1.4 Hz, 1, HI'), 8.23 (s, 2, H2,8); '9F NMR (MeOH-d4) -194.91
(ddd, J4'-F= 27 Hz, J'b-F = 22 Hz, J3'-F= 54 Hz); MS (CI) m/ 255 (100, MH'); and other
properties as reported for unlabeled analog. 33
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CONCLUSION
Ribonucleotide reductases are the enzymes responsible for generating '-
deoxyribonucleotides, the monomeric precursors required for DNA biosynthesis and
DNA repair. For more than four decades, the structure of the enzymes, mechanisms of
action and design and synthesis of inhibitors have been extensively studied.
Since 1992, the most accepted mechanism for the nucleotide reduction by RNRs
is the one proposed by Stubbe (Bi ochenisrv, 1992, 31, 9752-9729). Abstraction of 3-
hydrogen atom from the nucleoside diphosphate by a transient thiyl radical at Cys439
was proposed to initiate the radical reduction/cascade.
In 1996, Fontecave and coworkers showed that a substrate analog of the enzyme,
'-deoxy-'-mercaptouridine 5'-diphosphate, was a very efficient inactivator of RNR.
They proposed that in the presence of oxygen a mixed disulfide is produced between the
substrate analog and the protein and that homolytic cleavage of '-carbon-sulfur bond
generates the perthiyl radical observed by EPR spectroscopy.
Our first target in this thesis was design and synthesis of 9-(2-thio-o-D-
arabinofuranosyl)adenine '-diphosphate as a valuable probe to study the mechanism of
inhibition of ribonucleotide reductases. We predict that the thiyl radical formed at
cysteine 439 might be trapped by the arabino '-mercapto group via formation of R1
Cys439-2'-mercapto disulfide bridge leading to the inhibition of RDPR.
Efficient multi-step preparation of 9-(2-thio- -D-arabinofuranosyl)adenine
included: (i) protection of adenosine using Markiewicz methodology; (ii) triflation of 2'-
hydroxyl group; (iii) incorporation of a thioacetyl group with inversion of configuration
by nucleophilic displacement of '-0-triflate and (iv) deacetylation. Two different
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approaches were evaluated for the preparation of mixed disulfides, which were used for
protecting the reactive thiol group.
In the first approach, protected mixed disulfide was prepared by treatment of 2'-
mercapto compound with DEAD and I-propanethiol in THF followed by desilylation.
We found that protection groups at 3' and 5'-hydroxyl groups were necessary in order to
overcome solubility problems.
In the second approach, preparation of disulfide was attempted employing a new
method recently developed in which 2-(trimethylslilyl)ethanethiol is used as a source of
sulfur. Displacement of the triflate group afforded 2'-S-[(2-trimethylsilyl)ethyl]-2'-
thinucleoside in good yield. However, reaction of the latter with
dimethyl(methylthio)sulfonium tetrafluoroborate failed probably due to instability of the
purine ring under reaction condition.
The 5'-phosphorylation was performed using Poulter's methodology, which is
based on the displacement of 5'-O-tosylate ester with the corresponding pyrophosphate
ion. The thionucleotide obtained is currently under biological studies. In addition to the
arabino-'-thioadenosine obtained, other thionucleoside analogs were also prepared using
the same multi-step procedure to be evaluated against different cancer lines.
The second target of this thesis was the synthesis of four fluorine-containing
nucleoside analogs in order to study the stereoelectronic effect of a [-fluorine substituent
in radical deoxygenation reactions. It is well known that the presence of a fluorine atom
in the sugar moiety of nucleoside analogs not only changes the conformation of tle
molecule, but also its biological activity.
61
Employin Pankiewicz's methodology we prepared the -deoxy-9-
fluor-oadenosine and its arabino epimer as well as 3'-deoxy-3-fluoroadenosine and its
xylo epimer. Regioselective silylation (05') of the fluoro nucleosides and radical
leoxygenation of the corresponding phenoxythiocarbonyl esters gave four deuterium
labeled 2',3-dideoxy-2' (or 3) fluoronucleoside analogs. The ratio of deuterium
incorporation was determined by using 'H NMR on the bases of vicinal coupling constant
analysis (Jru and 4J
Our results clearly show that the steric effect of the heterocyclic base from the f-
face of the SuIar is decisive, favoring the incorporation of deuterium from the less
hindered a-face. However, the presence of a -fluorine substituent enhances the anti-
selectivity of deuterium abstraction relative to fluorine position in the sugar ring.
All the intermediates and the products were characterized by using 'H NMR, 'C
NMR, 3P NMR, and 'F NMR. Isotopic enhancement was confirmed using MS.
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